Biomarker and precision therapy for inflammatory disease

Abstract

The present disclosure provides a biomarker for accumulation of neutrophil extracellular traps (NETs) or extracellular chromatin. The present disclosure also provides methods for the treatment for inflammatory disease, including methods of predicting response to treatment, methods of patient selection for treatment, and determination of therapeutic dose.

Description

[0001]NTR-016PC / 119601-5016 BIOMARKER AND PRECISION THERAPY FOR INFLAMMATORY DISEASE PRIORITY This application claims the benefit of, and priority to, U.S. Provisional Application No. 63 / 542,824, filed October 6, 2023, the contents of which are hereby incorporated by reference in their entirety. DESCRIPTION OF THE XML FILE SUBMITTED ELECTRONICALLY This application contains a sequence listing. The sequence listing has been submitted electronically via EFS-Web as an XML entitled “NTR-016PC_119601- 5016_Sequence_Listing.xml.” The sequence listing is 524,398 bytes in size, and was created on or about October 6, 2024. The sequence listing is hereby incorporated by reference in its entirety. BACKGROUND Inflammatory and autoimmune disease (including but not limited to systemic lupus erythematosus, or SLE) typically progress through periods of relapse or “flare-up” and intermittent periods of remission. By discriminating and / or predicting patients with active and inactive disease, patients with inflammatory diseases can be more effectively treated with pharmacological and biologic agents. However, biomarkers are needed for discriminating subjects with active disease, and / or monitoring treatment, to allow for more effective treatment. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A and FIG. 1B show that DNASE 1-Like 3 (D1L3) enzyme rapidly and specifically disassembles chromatin in nucleosomes and then degrades the DNA further. FIG.1A shows a schematic representation of the chromatin substrate and nucleosomal units. FIG.1B compares enzymatic activity of D1L3 on chromatin substrate in comparison with DNASE 1. As shown, DNASE 1 digests chromatin to generate fragments of random sizes, indicating a lack of preferential location of digestion. In addition, the DNA persists even after 1 hour, suggesting the DNASE 1 is inefficient in digesting chromatin. On the other hand, D1L3 digests chromatin to generate a ladder of fragments of distinct sizes that are DB1 / 151380125.4 1 NTR-016PC / 119601-5016 consistent with digestion in the linker regions of nucleosomes, leading to production of mononucleosomes and oligonucleosomes, followed by an efficient complete digestion, as indicated by near absence of any DNA after 15 minutes of digestion. FIG. 2A to FIG. 2C demonstrate that D1L3 enzyme can generate circulating nucleosomes in blood. FIG.2A shows a schematic representation of the experiment. FIG. 2B is a dot plot showing levels of circulating DNA in wild type or Dnase1l3 knockout mice using EDTA plasma samples obtained at baseline and 6 hours after the injection of necrotic human male cells. FIG. 2C shows the results of a PCR-based assay for human Y chromosomal DNA in wild type mouse EDTA plasma samples obtained at baseline and 6 hours after the injection of necrotic human male cells. FIG. 2D shows the results of an agarose gel electrophoresis-based assay for DNA in wild type (i.e., D1L3+) mouse EDTA plasma samples obtained 6 hours after the injection of the necrotic cells. The ladder of fragments of distinct sizes is consistent with a D1L3 digestion, leading to production of mononucleosomes and oligonucleosomes. FIG. 3A to FIG. 3C show identification of a biomarker for accumulation of neutrophil extracellular traps (NETs) or extracellular chromatin. FIG.3A shows a library of human genomic repeat elements derived using the Dfam database (left panel) and a schematic illustration of the strategy used to evaluate the genomic repeat elements as biomarkers. FIG.3B shows two types of amplification products. Type A is smaller than 150 base pairs and resistant to DNASE1L3 fragmentation, i.e., it is an end product of D1L3 activity. Type B is larger than 150 base pairs and sensitive to D1L3 fragmentation, i.e., it is a substrate and / or intermediate degradation product. FIG.3C is a dot plot of percent signal change in NETs compared to fully degraded chromatin as a function of qPCR efficiency. FIG.4A and FIG.4B demonstrate that COVID-19 patients have high NET burden in tissues, which is alleviated by the treatment with NTR-441 (SEQ ID NO: 137), an engineered D1L3 drug candidate. FIG.4A is a line graph showing a time course of levels of an AluYm1 amplicon Type B, i.e., an intermediate degradation product in EDTA-plasma samples. Here plasma is representative of the patient’s blood circulation. The transient increase of an AluYm1 amplicon Type B indicated intermediate degradation products of NETs, which are generated by NTR-441-mediated digestion of NETs in tissues. DB1 / 151380125.4 2 NTR-016PC / 119601-5016 Intermediate degradation products are further degraded to mono-nucleosomes, i.e., an AluYm1 amplicon Type A. FIG.4B is a dot plot showing the maximal levels of an AluYm1 amplicon Type B, i.e., an intermediate degradation product, in EDTA-plasma samples. FIG. 5A and FIG. 5B demonstrate that a distinct cytokine profile before administration of NTR-441 predicted the extent of a repeated element amplicon of the hyper- nucleosome length marker (e.g., the AluYm1 amplicon Type B) that is detectable in EDTA- plasma samples derived from COVID-19 patients treated with NTR-441. FIG. 5A is a scatterplot of rho values of Spearman correlation of pre-dose levels of 45 cytokines with the increase of the AluYm1 amplicon Type B in EDTA-plasma samples after infusion of NTR- 441 plotted as a function of probability value (p value). FIG. 5B is a scatter plot showing the maximal levels of the AluYm1 amplicon Type B in EDTA-plasma samples plotted as a function of the levels of pre-dose IL-10. FIG.6A and FIG.6B demonstrate that distinct cytokine profile after administration of NTR-441 predicted the efficacy NTR-441 in generating the repeated element amplicon of the hyper-nucleosome length marker (e.g., the AluYm1 amplicon Type B) in EDTA- plasma samples derived from COVID-19 patients. FIG.6A is a line graph showing a time course of the levels of serum G-CSF in patients that showed the AluYm1 amplicon Type B upon NTR-441 treatment. FIG.6B shows the p values for statistical significance of changes in the levels of G-CSF, IL-6 and CXCL10 at indicated timepoints compared to baseline. FIG.7A and FIG.7B demonstrate that the repeated element amplicon of the hyper- nucleosome length marker (e.g., the AluYm1 amplicon Type B) in serum samples predicts the presence of neutrophil extracellular traps (NETs) in diseases associated with NETs. Here, the clotting activator in the serum tubes induces the production of undigested or incompletely digested NETs by blood cells, which can be detected by AluYm1 amplicon Type B. FIG. 7A is a dot plot showing the levels of AluYm1 amplicon Type B in serum samples of controls, SLE patients, and COVID-19 patients. FIG.7B is a dot plot showing the levels of AluYm1 amplicon 1 in serum samples of SLE patients that are clinically active and clinically inactive. FIG.8A and FIG.8B demonstrate that the repeated element amplicon of the hyper- nucleosome length marker (e.g., the AluYm1 amplicon Type B in relation to AluYm1 DB1 / 151380125.4 3 NTR-016PC / 119601-5016 amplicon Type A) in serum samples from healthy subjects helps determine clinical dose. FIG. 8A is a line graph showing the concentration of the AluYm1 amplicon Type B in relation to AluYm1 amplicon Type A in the pool of all circulating DNA in serum collected from healthy subjects after receiving a single dose of NTR-441. FIG. 8B is a line graph showing the concentration of mononucleosomes in the pool of all circulating DNA in serum collected from healthy subjects after receiving a single dose of NTR-441. FIG. 9A to FIG. 9C show illustrative FIG. 9A shows an illustrative lateral flow cartridge incorporating a cell-separator pad, capable of efficiently separating plasma from blood cells. FIG.9B shows an illustrative lateral flow test (LFT) that employs ultra-bright gold nanoshell reporters (nanoComposix) to increase sensitivity and visualize the biomarker at the test line without instrumentation. FIG. 9C shows amplification and visualization of the AluYm1 amplicon Type B using conventional PCR and detection on an AmpliDetect™ lateral flow cartridge. DETAILED DESCRIPTION The present disclosure in various aspects and embodiments provides a biomarker for inflammatory disease, to discriminate subjects with active and inactive disease, and provides a precision therapy for patients with inflammatory diseases, including but not limited to systemic lupus erythematosus (SLE) and other autoimmune conditions. In embodiments, the biomarker relates to Neutrophil Extracellular Traps (NET) and / or chromatin degradation products. In aspects and embodiments, the disclosure provides a method for detecting a marker for an inflammatory disease. The method comprises determining the level of a DNA fragment of a genomic repeat element, as described herein, in a subject sample. In aspects and embodiments, the present disclosure provides a method for treating a subject for an inflammatory disease. The method comprises administering a treatment for the inflammatory disease, where the subject exhibits an elevated level of the DNA fragment derived from a repetitive DNA element in a biological sample. In various embodiments, the DNA fragment of a genomic repeat element is derived from AluYm1, which is a marker of NET and / or chromatin degradation products. In DB1 / 151380125.4 4 NTR-016PC / 119601-5016 embodiments, the DNA fragment of a genomic repeat element is greater than 150 base pairs (bp), and represents intermediate NET and / or chromatin degradation products. In some embodiments, the DNA fragment derived from AluYm1 is less than about 500 bp, or less than about 400 bp, or less than about 300 bp, or less than about 250 bp, or less than about 200 bp. In some embodiments, the DNA fragment derived from AluYm1 is more than about 160 bp, or more than about 180 bp, or more than about 200 bp, or more than about 225 bp, or more than about 250 bp. In embodiments, the DNA fragment derived from AluYm1 is about 200 bp. In embodiments, the DNA fragment derived from AluYm1 comprises a nucleotide sequence substantially represented by a nucleotide sequence selected from SEQ ID NOs: 128-136, including natural variants thereof, which represent intermediate degradation products, and are sometimes referred to herein Type B amplicons. In some embodiments, the DNA fragment is amplified from the sample or is detected after direct capture. In some embodiments, the DNA fragment is amplified by PCR. In some embodiments, the method uses forward and reverse primers selected from SEQ ID NOs: 7- 127. In some embodiments, the forward primer has a nucleotide sequences selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66. In some embodiments, the reverse primer has a nucleotide sequences selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 38, and the reverse primers has a nucleotide sequence of SEQ ID NO: 39. In another illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 38, and the reverse primers has a nucleotide sequence of SEQ ID NO: 49. In still other embodiments, the DNA fragment is smaller than 150 base pairs, and represents fully degraded NETs and / or chromatin by D1L3 enzyme. Such embodiments are sometimes referred to herein as Type A amplicons. Illustrative Type A amplicons have nucleic acid sequences selected from SEQ ID NOs: 128-354. In some embodiments, the DNA fragment is amplified from the sample or is detected after direct capture. In some embodiments, the DNA fragment is amplified by PCR. In some embodiments, the method uses forward and reverse primers selected from SEQ ID NOs: 7- DB1 / 151380125.4 5 NTR-016PC / 119601-5016 127. In some embodiments, the forward primer has a nucleotide sequences selected from SEQ ID NOs: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, and 126. In some embodiments, the reverse primer has a nucleotide sequences selected from SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127. In some embodiments, the forward primer has a nucleotide sequences selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66. In some embodiments, the reverse primer has a nucleotide sequences selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 54, and the reverse primers has a nucleotide sequence of SEQ ID NO: 37. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 54, and the reverse primers has a nucleotide sequence of SEQ ID NO: 39. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 54, and the reverse primers has a nucleotide sequence of SEQ ID NO: 41. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 54, and the reverse primers has a nucleotide sequence of SEQ ID NO: 43. In embodiments, Type A and Type B amplicons are detected (FIG.3B). In some embodiments, the DNA fragment is quantified by qPCR. In embodiments, the qPCR is performed using TAQMAN. Generally, a real-time polymerase chain reaction (qPCR) monitors the amplification of a targeted DNA molecule during the PCR, i.e. in real- time. Real-time PCR can be used quantitatively, and semi-quantitatively. Two common methods for the detection of PCR products in real-time PCR are: (1) non-specific fluorescent dyes that intercalate with any double-stranded DNA (e.g., SYBR Green (I or II)), and (2) sequence-specific DNA probes that are labelled with a fluorescent reporter which permits detection only after hybridization of the probe with its complementary sequence (e.g. TAQMAN). DB1 / 151380125.4 6 NTR-016PC / 119601-5016 In some embodiments, the assay format is TAQMAN real-time PCR. TAQMAN probes are hydrolysis probes that are designed to increase the specificity of quantitative PCR. The TAQMAN probe principle relies on the 5′ to 3′ exonuclease activity of Taq polymerase to cleave a dual-labeled probe during hybridization to the complementary target sequence, with fluorophore-based detection. TAQMAN probes are dual labeled with a fluorophore and a quencher, and when the fluorophore is cleaved from the oligonucleotide probe by the Taq exonuclease activity, the fluorophore signal is detected (e.g., the signal is no longer quenched by the proximity of the labels). As in other quantitative PCR methods, the resulting fluorescence signal permits quantitative measurements of the accumulation of the product during the exponential stages of the PCR. The TAQMAN probe format provides high sensitivity and specificity of the detection. In some embodiments, the DNA fragment is amplified by isothermal amplification. In some embodiments, the isothermal amplification is Recombinase Polymerase Amplification (RPA), Loop-Mediated Isothermal Amplification (LAMP), or Single Primer Isothermal Amplification (SPIA). In some embodiments, the isothermal amplification employs a forward primer having a nucleobase sequence selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66. In some embodiments, the isothermal amplification employs a reverse primer having a nucleobase sequence selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 54, and the reverse primers has a nucleotide sequence of SEQ ID NO: 43. In an illustrative embodiment, the forward primer has a nucleotide sequence of SEQ ID NO: 54, and the reverse primers has a nucleotide sequence of SEQ ID NO: 41. In embodiments, the DNA fragment is detected and / or quantified by a lateral flow test. For example, the DNA fragment can be amplified with primer(s) conjugated with a detectable label and a capturable moiety. An LFA can be composed of a nitrocellulose membrane, as well as other components such as a sample pad, conjugate pad, wicking or absorbent pad and backing pad, as known in the art. Nitrocellulose membranes are commonly used as they facilitate a support capable of use for both reaction and detection. Capture biomolecules, for example antibodies, are preferably deposited on the nitrocellulose DB1 / 151380125.4 7 NTR-016PC / 119601-5016 to form test and control lines via a combination of electrostatic interactions, hydrogen bonds and / or hydrophobic interactions. In embodiments employing an LFA, the DNA fragment is amplified with primer(s) conjugated with a detectable label and a capturable moiety. Non-limiting examples of nucleic acid labels that may be utilized include a fluorescein (e.g., but not limited to, fluorescein amidite, fluorescein isothiocyanate (FITC), or carboxyfluorescein), digoxin, digoxigenin, Cy5, Texas Red, 2,4-dinitrophenyl (DNP), fluorescent molecules, quantum dots nanocrystals, semiconductor nanocrystals, upconverting phosphors, bioluminescent markers, luminescent oxygen channeling, enzyme labels, paramagnetic particles, latex particles, and the like. In embodiments, the reverse primer for each oligonucleotide pair is conjugated to a chemical or biochemical capture moiety for diagnostic applications, wherein the capture moiety is one member of a specific binding pair. In some embodiments, the other member of the specific binding pair is immobilized on a surface or other form of substrate so as to “capture” amplification products that contain the capture moiety. Non-limiting examples of moieties to which the reverse primers can be conjugated include biotin or streptavidin and antibody / antigen pairs, among others. In embodiments, an elevated level of the DNA fragment is indicative of active inflammatory disease in the subject. In embodiments, the inflammatory disease is an autoimmune disease, such as systemic lupus erythematosus (SLE), and which may involve lupus nephritis. In embodiments, the subject has a loss-of-function mutation in one or both dnase1l3 genes. That is, the subject may have an inflammatory disease or autoimmune disease (such as SLE), and the level of the DNA fragment in a sample from the subject is assayed to determine whether the subject has active disease or has inactive disease (e.g., remission). Patients with active disease may receive treatment to mitigate the disease including potential flare-up or relapse. In embodiments, the subject has an autoimmune disease selected from SLE, rheumatoid arthritis, multiple sclerosis, psoriasis, vasculitis, inflammatory bowel disease, and dermatomyositis. In embodiments, the subject has gout or a coronavirus infection (e.g., SARS-CoV2 or COVID-19). In embodiments, the subject suffers from or is at risk of DB1 / 151380125.4 8 NTR-016PC / 119601-5016 thrombotic vascular disease, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and sepsis. Other inflammatory conditions involving NETs are known in the art, and are described in US Patent No.10,696,956, which is hereby incorporated by reference in its entirety. SLE is a chronic relapsing autoimmune disease that affects more than five million people worldwide and 200,000 individuals in the U.S. Clinical manifestations of SLE include arthritis, rashes, serositis, kidney disease, hematologic, and neuropsychiatric complications. Active SLE is characterized by widespread inflammation and antigen- antibody immune complex deposition in different organ systems. Anti-nuclear (ANA) and anti-double-stranded DNA (anti-dsDNA) antibodies are the serological hallmark of SLE. ANAs are directed against chromatin and its individual components, including double- stranded DNA (dsDNA), histones, and ribonucleoproteins. Active SLE is characterized by T- and B-cell responses to the nuclear antigens, with intensive antigen-antibody immune complex deposition in different organs and systems. NETs play a significant role in the pathogenesis of SLE and other autoimmune and inflammatory conditions, and thus are a therapeutic target in patients with such disorders. A critical feature of NETs is that their DNA is intact and can exceed one hundred million base pairs in length, thereby exposing a reactive surface that is several thousand-fold larger than the neutrophils from which they derive. Importantly, DNA in NETs is organized as chromatin, a macromolecular assembly of histone proteins wrapped by double-stranded DNA (dsDNA). The length of DNA wrapped around each histone core is approximately 150-base pairs. Each histone-DNA unit is referred to as a nucleosome. The enormous NET burden in inflammatory diseases coupled with an inability to degrade and clear circulating poly-nucleosomal DNA leads to the formation of macro-immune complexes that trigger an inflammatory reaction with subsequent tissue damage. Further, loss-of-function mutations in Dnase1l3 can cause familial forms of SLE characterized by a severe and early onset of the disease, highlighting the critical function of DNASE1L3 in this disease. Thus, in some embodiments, the subject has a loss-of-function mutation in one or both Dnase1l3 genes. DB1 / 151380125.4 9 NTR-016PC / 119601-5016 SLE is categorized as mild, moderate, or severe. Mild SLE is defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of <6, or one British Isles Lupus Assessment Group (BILAG) B score. Moderate SLE is defined as SLEDAI-2K score between 6-10 and / or two or more BILAG B scores. Severe SLE is defined as SLEDAI- 2K score of >10 and / or at least one BILAG A score. In embodiments, the subject has mild, moderate, or severe SLE. Treatment of SLE often involves long-term immunosuppression, which carries the risk of drug toxicity and impacts quality of life. Mild SLE is typically managed with NSAIDS, antimalarials, and / or low-dose corticosteroids, while moderate SLE is managed with higher doses of corticosteroids and immunosuppressive medications. Severe SLE requires potent immunosuppressive agents, chemotherapy and in extreme cases, plasmapheresis or cellular therapy. Exemplary disease modifying immunosuppressive agents for treatment of SLE include azathioprine, mycophenolate mofetil, calcineurin inhibitors and cyclophosphamide, (for Lupus Nephritis (LN)). Biologics for the treatment of SLE include belimumab and anifrolumab. However, despite treatment, many patients continue to suffer from disease exacerbations (flares) of varying severity and progressive disease. There are concerns that the existing diagnostic framework for SLE does not adequately capture dynamic disease changes or specific organ involvement, which could impact treatment decisions. Treatments for SLE often involve the long-term administration of a combination of different drugs over many years. However, despite treatment many patients continue to suffer from disease exacerbations (flares) of varying severity. D1L3 and engineered variants provide an opportunity to improve therapy for SLE (and other rheumatic and inflammatory diseases including gout and vasculitis), as a substitute or combination with existing therapies. In embodiments, the sample is blood, serum, plasma, or urine. For example, plasma samples represent the level of the target DNA fragment in the subject’s circulation. Alternatively, the sample is serum. Processing of a blood sample as serum can activate production of NETs in the sample, thereby assaying for the level of NET formation in the subject. DB1 / 151380125.4 10 NTR-016PC / 119601-5016 In embodiments, the subject is tested at a frequency of approximately daily to about once per month (e.g., about once per week), to monitor the subject for treatment. Alternatively, the subject is tested from once to 12 times per year, such as from 2 to about 8 times per year. In aspects and embodiments, the subject with an elevated level of the DNA fragment is treated with a DNase treatment, such as but not limited to a parenteral DNase treatment. In some embodiments, the DNase is DNase1, DNase1-like 1, DNase1-like 2, or DNase1- like 3. In some embodiments, the DNase is DNase1-like 3 (D1L3), and which is optionally fused to a carrier protein either directly or indirectly through a linker, and where the carrier protein is optionally albumin. Fusion to a carrier protein allows for pharmacodynamic enhancement. In some embodiments, the D1L3 enzyme has a full or partial deletion of the C-terminal basic domain. See US Patent Nos. 10,988,746; 11,840,712; and 11,578,314, which are hereby incorporated by reference in its entirety. In embodiments, the DNase therapy is a D1L3 enzyme as described in WO 2024 / 107701, which is hereby incorporated by reference in its entirety. In some embodiments, the D1L3 enzyme comprises an amino acid sequence that has at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity to amino acids 21 to 282 of SEQ ID NO: 833 (Isoform 1) or amino acids 21 to 252 of SEQ ID NO: 834 (Isoform 2). In some embodiments, the D1L3 enzyme comprises an N-terminal extension of at least four amino acids (e.g., 4 to about 18 amino acids). In embodiments, the first N-terminal amino acid is not a Met residue and is not a Gly residue (which can be subject to post- translational modification). In some embodiments, the last amino acid residue of the N- terminal extension is not a Ser residue, which can increase immunogenicity risk for D1L3. In some embodiments, the last amino acid residue of the N-terminal extension is a Gly residue. In some embodiments, the N-terminal extension is predominately Gly residues (i.e., more than 50% Gly residues). In some embodiments, the N-terminal extension comprises at least one Cysteine residue to provide for site-specific chemical conjugation, such as to polyethylene glycol, or disulfide dimerization. In some embodiments, the N-terminal extension comprises or consists of the amino acid sequence of SGGGG (SEQ ID NO: 835). DB1 / 151380125.4 11 NTR-016PC / 119601-5016 In some embodiments, the N-terminal extension comprises or consists of the amino acid sequence of CGGGG (SEQ ID NO: 836). In some embodiments, the D1L3 variant further comprises a C-terminal extension reducing heterogeneity. In some embodiments, the C-terminal amino acid is a lysine (Lys) or an arginine (Arg). In some embodiments, the C-terminal extension comprises or consists of the amino acid sequence SSR, which can be employed in some embodiments for D1L3 variants having whole or partial deletions of the C-terminal basic domain. In still other embodiments, the D1L3 is encoded and expressed with a 20 amino acid deletion of the basic domain, thereby having the sequence SSR at the C-terminus. In some embodiments, the D1L3 variant comprises a deletion of at least three, or at least five, or at least eight, or at least ten, or at least twelve, or at least fifteen, or at least eighteen, or at least twenty, or all 23 amino acids of a C-terminal basic domain (BD) defined by amino acids 283 to 305 of SEQ ID NO: 833. In some embodiments, the D1L3 variant comprises a deletion of 20 amino acids of the C-terminal basic domain (BD) defined by amino acids 283 to 305 of SEQ ID NO: 833, such that the D1L3 variant comprises the C- terminal extension of the sequence SSR. In some embodiments, the D1L3 variant has a substitution of the amino acid corresponding to C48 of SEQ ID NO: 833. These variants can remove an unpaired cysteine that improves recombinant production and stability of the enzyme. In some embodiments, the disclosure provides a D1L3 dimer according to this disclosure that is optionally dimerized through disulfide bridge at C48. In some embodiments, the D1L3 variant comprises the incorporation of non-native cysteines, which can contribute to dimerization, including incorporation of non-native cysteines at the N- terminus. In such embodiments, the disclosure provides a D1L3 dimer, which can be used in therapy according to the disclosure. In some embodiments, the D1L3 variant comprises a substitution of cysteine at position 48 (C48) with respect to SEQ ID NO: 833, to further control dimerization positions. For example, the mutation can be selected from C48A, C48G, and C48S. In some embodiments, the substitution of C48 (e.g., to C48A or C48G) increases the enzymatic capacity (such as chromatin degradation) of the D1L3 enzyme. In some embodiments, the D1L3 variant has a C-terminal extension which comprises or consists of DB1 / 151380125.4 12 NTR-016PC / 119601-5016 the amino acid sequence SSR and a mutation of C48A with respect to SEQ ID NO: 833 (numbered without the signal peptide). Exemplary D1L3 variants in accordance with this disclosure include SEQ ID NO: 837, SEQ ID NO: 838, SEQ ID NO: 839, SEQ ID NO: 840, SEQ ID NO: 841, SEQ ID NO: 842, or SEQ ID NO: 843. In some embodiments, the D1L3 variant comprises a fusion or conjugation to a half- life extending moiety. In some embodiments, the polymer is a polyethylene glycol (PEG). In some embodiments, the PEG is conjugated to the N-terminus. In some embodiments, the PEG polymer connects two D1L3 variant molecules through their N-termini. In some embodiments, the PEG is conjugated to the C-terminus. In some embodiments, the PEG polymer connects two D1L3 variant molecules through their C-termini. In some embodiments, the treatment for the inflammatory or autoimmune disease comprises (or further comprises) administering an immunosuppressive drug. In embodiments, the treatment comprises one or more of corticosteroid, azathiopurine, mycophenolate mofetil, cyclophosphamide, voclosporin, belimumab and anifrolumab. In embodiments, the level of the DNA fragment is determined with EDTA plasma or serum, wherein the elevated level is elevated as compared to a reference value. In embodiments, the EDTA plasma sample is obtained from the subject about 5 minutes to 48 hours after administration of a DNase therapy, which is optionally DNase1-like 3 or a variant thereof as described. In such embodiments, the disclosure allows confirmation of target engagement by the DNase therapy. In embodiments, one or more EDTA plasma samples are obtained after at least about 15 minutes, or at least about 30 minutes, or at least about 1 hour, or at least about 2 hours, or at least about 3 hours, or at least about 4 hours, or at least about 6 hours, or at least about 8 hours, or at least about 12 hours, or at least about 18 hours, or at least about 24 hours, or at least about 36 hours, or at least about 48 hours after administration of the DNase therapy. In embodiments, the method further comprises comparing relative abundance of the DNA fragment in the EDTA plasma with a baseline EDTA plasma obtained before administration of the DNase therapy to confirm therapeutic activity of the DNase therapy. DB1 / 151380125.4 13 NTR-016PC / 119601-5016 In some embodiments, a greater abundance of the DNA fragment in EDTA plasma compared to the baseline EDTA plasma by a factor of at least about 1.5, or at least about 2, or at least about 4, or at least about 6, or at least about 8, or at least about 10, is indicative of targeting of extracellular trap (ET) and / or neutrophil extracellular trap (NET) by the DNase therapy. In some embodiments, the sample is serum. In some embodiments, the serum is obtained prior to the administration of the treatment and / or after administration of a treatment (such as but not limited to DNase therapy as described), and the abundance of the DNA fragments allows for tailoring of the therapeutic dose. In embodiments, the Type A and Type B amplicons are detected and / or quantified, to profile intermediate and full NET and / or chromatin degradation products present in the serum sample. In embodiments, the method further comprises comparing relative abundance of the DNA fragment in the serum with one or more reference values or baseline values. In embodiments, the reference values represent a relative abundance of the DNA fragment in serum for an active state of the inflammatory disease and / or inactive state of the inflammatory disease. In some embodiments, a greater abundance of the DNA fragment in serum compared to the one or more reference values by a factor of at least about 1.5, or at least about 2, or at least about 4, or at least about 6, or at least about 8, or at least about 10 is indicative of targeting of extracellular trap (ET) and / or neutrophil extracellular trap (NET) by the DNase therapy. In some embodiments, a reduction in the abundance of the DNA fragment by at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90% to a baseline value is indicative of a proper dose. In some embodiments, the method comprises or further comprises measuring the amount or activity of IL-10 and / or VEGF-A in the biological sample obtained from the subject. In some embodiments, the method comprises administering a DNase 1-like 3 enzyme or a derivative thereof to the subject if the biological sample has an elevated IL-10 and / or low VEGF-A compared to one or more reference values. In some embodiments, the biological sample is selected from blood, plasma, serum, or urine. In some embodiments, the amount or activity of IL-10 and / or VEGF-A is measured DB1 / 151380125.4 14 NTR-016PC / 119601-5016 by contacting the sample with one or more agents that specifically bind to amount or activity of IL-10 and / or VEGF-A. In some embodiments, the one or more agents that specifically bind to amount or activity of IL-10 and / or VEGF-A is an antibody or fragment thereof. In some embodiments, the method comprises or further comprises measuring the amount or activity of G-CSF, IL-6 and / or CXCL10 a post-dose biological sample obtained from the subject, wherein the subject has been administered a DNase 1-like 3 enzyme or a derivative thereof. In some embodiments, the method comprises continuing therapy with the DNase1-like 3 or a variant thereof if the amount or activity of G-CSF, IL-6 and / or CXCL10 the post-dose biological sample is lower as compared to one or more reference values. In some embodiments, the biological sample is selected from blood, plasma, serum, or urine. In some embodiments, the amount or activity of IL-10 and / or VEGF-A is measured by contacting the sample with one or more agents that specifically bind to amount or activity of G-CSF, IL-6 and / or CXCL10. In some embodiments, the one or more agents that specifically bind to amount or activity of G-CSF, IL-6 and / or CXCL10 is an antibody or fragment thereof. In an aspect, the present disclosure further provides kits for the detection and / or amplification of the DNA fragment derived from a repetitive DNA element. The kit comprise a forward and reverse primer as described herein, and optionally one or more detection reagents. For example, but not by way of limitation, the kits may include one or more of the following components: (i) at least one reaction chamber for performing a polymerase amplification reaction; and / or (ii) at least one nucleic acid lateral flow assay device; and / or (iii) at least one sample collection device. Any reaction chambers known in the art as applicable for use with amplification reactions (such as, but not limited to, RPA and PCR) may be utilized in accordance with the present disclosure. The reaction chambers may include one or more dried reagents for performing the amplification reactions. For example (but not by way of limitation), when the reaction is an RPA reaction, the reaction chambers may comprise a dried reagent composition that includes a recombinase, a polymerase, and a single-stranded DNA binding protein. Non-limiting examples of reaction chambers that may be utilized in accordance with DB1 / 151380125.4 15 NTR-016PC / 119601-5016 the present disclosure include those disclosed in U.S. 10,036,057 and 10,538,760, the contents of which are hereby expressly incorporated herein by reference in their entirety. Any nucleic acid lateral flow assay devices known in the art for detection of amplification products may be utilized in accordance with the present disclosure. Such devices are well known in the art and commercially available; two non-limiting examples thereof include Milenia HybriDetect lateral flow dipsticks (Milenia Biotec GmbH, GieBen, Germany) and PCRD nucleic acid lateral flow immunoassay (NALFIA) cassettes (Abingdon Health, York, UK). Further non-limiting examples of nucleic acid lateral flow assay devices utilized in combination with RPA reaction chambers are disclosed in U.S. Pat. Nos. 10,036,057 and 10,538,760, the contents of which are hereby expressly incorporated herein by reference in their entirety. As used herein, unless the context requires otherwise, the term “about” means a value that is ±10% of a reference value. Various aspects and embodiments of this disclosure will be apparent from the following non-limiting examples. EXAMPLES Example 1: Characterization of Chromatin Degradation Activity of DNase 1-Like 3 (D1L3) in Vitro DNase activity of D1L3 on chromatin substrate was characterized in comparison with DNASE 1 using high molecular weight (HMW) chromatin (FIG. 1A, e.g., purified nuclei from HEK293 cells). Briefly, HMW chromatin was first incubated with the DNase enzyme, followed by DNA isolation and visualization via agarose gel electrophoresis (AGE). As shown in FIG.1B, D1L3 digested chromatin in seconds to generate a ladder of fragments of distinct sizes that are consistent with digestion in the linker regions of nucleosomes, leaving isolated mostly mononucleosomes and some oligonucleosomes. The DNA from mononucleosomes and oligonucleosomes were then completely degraded in less than 15 minutes (FIG.1B). On the other hand, DNASE 1 digested chromatin inefficiently as shown by persistence of DNA even after 1 hour of digestion reaction (FIG. 1B). DB1 / 151380125.4 16 NTR-016PC / 119601-5016 Moreover, DNASE 1 generated a streak of degraded DNA with no discernible structure (FIG.1B). These results indicated a lack of preferential location of digestion by DNASE 1. These results suggest D1L3 enzyme rapidly and specifically disassembles chromatin in nucleosomes and then degrades the DNA further. Example 2: Characterization of Chromatin Degradation Activity of D1L3 in Vivo DNase 1-Like 3 (D1L3) is secreted by immune cells into blood circulation. It is the dominant DNA degrading enzyme in blood. DNASE 1 is the main DNase in urine. D1L3 plays a major role in shaping plasma cell-free DNA fragmentation pattern. Zhou et al., Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs, Proc. Natl. Acad. Sci. USA 120 (17) e2220982120. Serum DNase activity on chromatin substrate was characterized in wild type female mice in comparison with Dnase1l3 knockout mice by injecting (i.p.) necrotic human male cells (FIG.2A). EDTA plasma was prepared from blood extracted from mice receiving necrotic human male cells, and total circulating DNA was quantified at baseline and 6 hours after the injection of the necrotic cells. As shown in FIG. 2B, wild type mice showed significant amount of circulating DNA in plasma 6 hours after the injection of the necrotic cells but not at baseline, indicating that the observed circulating DNA was formed from the necrotic cells. In contrast, Dnase1l3 knockout mice showed only background level of total circulating DNA both at baseline and 6 hours after the injection of the necrotic cells (FIG.2B). The difference in the amount of total circulating DNA in wild type mice was significantly higher (p < 0.0001) compared to the DNASE1L3- / -mice (FIG.2B). These results indicate that plasma D1L3 digests the chromatin of necrotic cells to generate the circulating DNA. To confirm that the observed circulating DNA was derived from necrotic cells, a human Y-chromosome-specific marker was amplified using a polymerase chain reaction (PCR). As shown in FIG.2C, human Y chromosomal DNA was amplified from wild type mouse plasma samples obtained 6 hours after the injection of the necrotic cells but not at baseline. These results show that the circulating DNA was derived from necrotic human male cells. The circulating DNA from wild type mice was resolved using agarose gel electrophoresis and visualized. As shown in FIG.2D, the circulating DNA formed a ladder of fragments of distinct sizes and is consistent with the DNA being mostly from DB1 / 151380125.4 17 NTR-016PC / 119601-5016 mononucleosomes and some oligonucleosomes. This digestion pattern is consistent with a D1L3 digestion of chromatin (FIG.1B). Example 3: Developing a Biomarker for Accumulation of Neutrophil Extracellular Traps (NETs) or Extracellular Chromatin Experiments were performed to identify a nucleosome-based biomarker that is enriched in conditions that feature accumulation of NETs or extracellular chromatin. Briefly, the Dfam database was used to assemble a library of human genomic repeat elements (FIG. 3A). Targeted elements included transposable elements, including Long Interspersed Nuclear Elements (LINEs) and Short Interspersed Nuclear Elements (SINEs). A total of 91 target sequences were scored based on their length and frequency within the human genome. Since ∼147 bp of DNA is wrapped around a mono nucleosome, DNA sequences shorter than 150 base pairs were excluded from further development. The following target sequences were evaluated for obtaining a nucleosome-based biomarker: AluSp (DF0000042.4), AluYh3 (DF0001318.2), AluYm1 (DF0001154.2), AluYa5 (DF0000053.4), AluSq (DF0000043.4), AluSq2 (DF0000045.4), AluYk2 (DF0001169.2), AluJo (DF0000034.4), AluJr (DF0000035.4), AluSz (DF0000051.4), AluSx1 (DF0000048.4), AluJb (DF0000007.4), AluSz6 (DF0000052.4), AluSx (DF0000047.4), AluJr4 (DF0000036.4), AluYk4 (DF0000066.4), AluSq10 (DF0000044.4), AluYg6 (DF0000634.4), AluYb9 (DF0000056.4), AluYb8 (DF0000055.4), AluYk12 (DF0000065.4), AluYk11 (DF0000064.4), AluYj4 (DF0001320.2), AluY (DF0000002.4), AluYi6_(DF0001316.2), AluSc8 (DF0000038.4), AluYi6 (DF0001197.2), AluYf1 (DF0001317.2), AluYk3 (DF0001145.2), AluYh7 (DF0001321.2), AluYh9 (DF0000063.4), AluSq4 (DF0000046.4), AluSx3 (DF0000049.4), AluYe5 (DF0001240.2), AluSg4 (DF0000040.4), AluYe6 (DF0001174.2), AluYa8 (DF0000054.4), AluSg (DF0000039.4), AluSx4 (DF0000050.4), AluSc (DF0000003.4), AluSc5 (DF0000037.4), AluSg7 (DF0000041.4), AluYc3 (DF0000058.4), AluYd8 (DF0000060.4), AluYc (DF0000057.4), L1M1_(DF0000227.4), L1M1 (DF0000228.4), L1P4_(DF0000326.4), L1PB_(DF0000354.4), L1P3_(DF0000320.4), L1P1_(DF0000316.4), L1PA12_(DF0000778.4), L1PBa_(DF0000352.4), L1PA15-16 (DF0000334.4), L1PA13_(DF0000332.4), L1PA14_(DF0000773.4), L1P4a_(DF0000321.4), DB1 / 151380125.4 18 NTR-016PC / 119601-5016 L1PA10_(DF0000328.4), L1P1_(DF0000315.4), L1HS_(DF0000226.4), L1P4d_(DF0000324.4), L1P4b_(DF0000322.4), L1PA17_(DF0000338.4), L1P3_(DF0000318.4), L1PBa1_(DF0000351.4), 1P4c_(DF0000323.5), L1P4e_(DF0000325.4), L1P3b_(DF0000319.4), L1PBb_(DF0000353.4), L1MA3_(DF0000258.5), L1MA2_(DF0000257.4), L1MA1_(DF0000256.4), L1PA11_(DF0000329.4), L1PA8_(DF0000345.4), L1PA10_(DF0000327.4), L1PA12_(DF0000330.4), L1PA17_(DF0000337.4), L1PA16_(DF0000336.4), L1PA15_(DF0000335.4), L1PA13_(DF0000331.4), L1PA14_(DF0000333.4), L1PA4_(DF0000341.4), L1PA3_(DF0000340.4), L1PA2_(DF0000339.4), L1HS_(DF0000225.4), L1PB3_(DF0000349.4), L1PA7_(DF0000344.4), L1PA5_(DF0000342.4), L1PB2_(DF0000348.4), L1PB1 (DF0000347.4), and L1PA8A_(DF0000346.4). Seventeen sequences were selected, and top-ranked sequences included LINE-1 family members (L1M1, L1P4, L1PB) and ALU family members (AluSp, AluYh3, AluYm1) with a length of > 310 base pairs. Illustrative target consensus sequences are SEQ ID NOs: 1-6. A library of interchangeable forward and reverse primers was designed and combined in a matrix format, producing a screening library of potential diagnostic assays, which differed by targeting variable positions and / or variable amplicon length. Illustrative primers are SEQ ID NOs: 7-127. As shown in Example 2, the necrotic cells or their chromatin and NETs remain in tissue. Therefore, they are not easily detected in plasma or serum. Therefore, either nucleosomes, the end products of D1L3 activity, or intermediates of NETs degradation such as olinonucleosomes are easily detectable in plasma or serum. FIG.3B shows two types of illustrative amplification products. Type A is smaller than 150 base pairs and resistant to DNASE1L3 fragmentation, i.e., it is an end product of D1L3 activity. Type B is larger than 150 base pairs and sensitive to D1L3 fragmentation, i.e., it is a substrate and / or intermediate degradation product. After initial evaluation using clinical serum samples from healthy subjects (collected for an NTR-441 trial) a primer pair, termed the AluYm1 amplicon 1, which is amplified by SEQ ID NOs 128-136, was selected. Serum is generated by allowing the blood to clot, DB1 / 151380125.4 19 NTR-016PC / 119601-5016 optionally by exposing blood to an activated surface (e.g., silica). Clotting causes the activation of clotting factors, platelets, and neutrophils, leading to generation of NETs. Thus, unlike plasma, serum is enriched with undigested DNA-fragments from NETs that are generated during blood clotting. As disclosed herein, serum can be used for determining an effective dose of DNase therapy during Phase 1 studies in healthy subjects as well as in later stage clinical development in patients. FIG. 3C is a dot plot of percent signal change in NETs compared to fully degraded chromatin as a function of qPCR efficiency. An AluYm1 amplicon is strongly reduced within 15 minutes and 4 hours after start of the infusion with NTR-441, when compared to pre-dose levels. NTR-441 is an engineered D1L3 enzyme having an N-terminal fusion to albumin through a Gly-Ser linker. Example 4: Demonstration of Target Engagement in High NET Burden Patients Treated with NTR-441 NTR-441 is a Albumin – D1L3 variant fusion protein. A randomized, placebo- controlled, double-blind, phase 1 study was conducted to assess the safety and tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of NTR-441 administered via i.v. infusion in healthy adults and COVID-19 patients that were hospitalized for COVID-19 pneumonia. Predose blood samples were taken in EDTA plasma tubes from healthy adults and COVID-19 patients that were hospitalized for COVID-19 pneumonia, and NTR-441 or placebo was administered via IV infusion. Blood samples were taken in EDTA plasma tubes at 4 hours, 8 hours, 12 hours, 24 hours and 48 hours post dosing. Plasma samples were prepared and assayed for the presence of the AluYm1 amplicon 1 using a quantitative PCR- based assay. As shown in FIG.4A, compared to predose samples, the levels of the AluYm1 amplicon 1 increased at 4, 8 or 24 hours post dosing in NTR-441-dosed patients, depending on the patient (this could be because of differences in ability of NTR-441 to access NETs). No dose dependent effect of NTR-441 was detected, which is consistent with the observation that the lowest dose of NTR-441, i.e., 0.3 mg / kg, showed potent target engagement in an ex vivo assay. In each patient that exhibited an increase in the levels of the AluYm1 amplicon 1, the subsequence sample showed a decrease of the AluYm1 amplicon 1 to background (FIG. 4A). The placebo-treated patients exhibited no such increase (or decrease) over 48 DB1 / 151380125.4 20 NTR-016PC / 119601-5016 hours (FIG.4A). The levels of the AluYm1 amplicon 1 spiked within 48 hours in 8 out of 9 COVID-19 patients receiving NTR-441 infusions, but not in COVID-19 patients receiving placebo (FIG. 4A). The levels of the AluYm1 amplicon 1 did not spike after infusion of NTR-441 in healthy subjects, corroborating the fact that the drug target, i.e., NETs and necrotic nuclei are not exposed in healthy subjects. FIG. 4B is a dot plot showing the maximal levels of the AluYm1 amplicon 1 in EDTA-plasma samples. As shown in FIG.4B, the maximal plasma concentration of the AluYm1 amplicon 1 was significantly higher (p < 0.0182) compared to placebo-treated patients. These results suggest that NETs and other extracellular chromatin is present in the tissues of patients (e.g., lungs). As discussed above, since the hyper-nucleosome length markers have length of over 150 bp, which exceeds the length of DNA in mono- nucleosomes, the amplicon detected represented incompletely digested chromatin / NETs in plasma because of the activity of NTR-441. Thus, these results indicate that an intermediate degradation product of NETs was temporarily increased in blood circulation after administration of NTR-441 into COVID-19 patients, confirming target engagement. The decrease of the NETs to background level indicated that NTR-441 completely degraded the oligonucleosonal or mononucleosonal DNA. Example 5: Cytokine Profile Before the Administration of NTR-441 Predicts Target Engagement of NTR-441 in COVID-19 Subjects A panel of 45 cytokines were measured in plasma samples of COVID-19 patients that were collected immediately before infusion of NTR-441. Pre-dose cytokine levels were correlated with the extent of target engagement and processing, defined as the increase of the AluYm1 amplicon 1 after infusion of NTR-441. FIG.5A is a scatterplot of rho values of Spearman correlation of pre-dose levels of 45 cytokines with the increase of the AluYm1 amplicon 1 in EDTA-plasma samples after infusion of NTR-441 plotted as a function of probability value (p value). Interleukin-10 (IL-10) levels showed a strong positive correlation with the AluYm1 amplicon 1 (Spearman rho = 0.833, p-value = 0.005; FIG.5A). Vascular Endothelial Growth Factor A (VEGF-A) levels showed a negative correlation with the AluYm1 amplicon 1 (Spearman rho = -0.833, p-value = 0.005; FIG.5A). DB1 / 151380125.4 21 NTR-016PC / 119601-5016 These results indicate that a distinct cytokine profile (IL-10HIGHand / or VEGF-ALOW) before administration of NTR-441 predicted the extent of target engagement in COVID-19 patients. These results suggest that the observed cytokine profile may be used for selecting patients for the treatment with NTR-441. Example 6: Cytokine Profile After the Administration of NTR-441 Predicted with Target Engagement of NTR-441 A panel of 45 cytokines was measured in plasma samples of COVID-19 patients that were collected immediately before, and a various time point after the infusion of NTR-441. Changes in the cytokine profile were analyzed in two groups of patients. The first group comprised the COVID-19 patients with the highest levels of the AluYm1 amplicon 1 after NTR-441 infusion. The second group included all 8 other COVID-19 patients, including the 3 patients that received placebo. As shown in FIG. 6A, among the 45 cytokines, G-CSF showed the most dramatic changes. It rapidly declined within 4 hours after NTR-441 infusion in patients with high AluYm1 amplicon 1 levels. G-CSF levels normalized within 24 hours and remained low levels for the remainder of the study duration (FIG. 6A). Other cytokines that showed significant decreases compared to pre-dose levels included IL-6 and CXCL10 (FIG.6B). NETs contain enzymatically active neutrophil serine proteases, which can degrade cytokines. Furthermore, neutrophil elastase specifically degrades G-CSF and antagonizes its function in granulopoiesis. Thus, these results indicate that target engagement and clearance by NTR-441 in COVID-19 patients triggers a potential negative feedback loop for granulopoeiesis. These results further indicate that a distinct cytokine profile featuring a decrease in G-CSF, IL-6 and / or CXCL10 after administration of NTR-441 predicted the extent of target engagement and clearance in COVID-19 patients. These results suggest that the observed cytokine profile may be used for selection patients for the treatment with NTR-441 or selection of NTR-441 for treatment of the patients. DB1 / 151380125.4 22 NTR-016PC / 119601-5016 Example 7: Level of NETs Biomarker in Serum Predicts the Presence of Neutrophil Extracellular Traps (NETs) in Diseases Associated with NETs Serum is generated by allowing the blood to clot, optionally by exposing blood to an activated surface (e.g., silica). Clotting causes the activation of clotting factors, platelets, and neutrophils, leading to generation of NETs. Thus, unlike plasma, serum is enriched with undigested DNA-fragments from NETs that are generated during blood clotting. Serum samples from patients suffering from diseases associated with NETs were studied for the amount of the AluYm1 amplicon Type B. Towards that, sera from COVID-19 patients or SLE patients were compared with sera from controls. FIG. 7A is a dot plot showing the levels of AluYm1 amplicon Type B in serum samples of controls, SLE patients, and COVID- 19 patients. As shown in FIG.7A, compared to control samples, the sera from SLE patients (p < 0.0001) and COVID-19 (p = 0.0576) showed a significant increase in the AluYm1 amplicon Type B. The sera from SLE patients that are clinically active were compared with sera from SLE patients that are clinically inactive. FIG.7B is a dot plot showing the levels of AluYm1 amplicon 1 in serum samples of SLE patients that are clinically active or inactive. As shown in FIG. 7B, compared to control samples, compared to sera from SLE patients that are clinically inactive the sera from SLE patients that are clinically active showed a significant increase in the AluYm1 amplicon 1 (p < 0.007). These results show that serum concentrations of AluYm1 amplicon 1 reflects the degree of neutrophils undergoing NETosis upon activation (e.g., during blood clotting), which is increased in patients with clinical symptoms of SLE compared to healthy controls. SLE patients without clinical symptoms, but increased serum levels of the AluYm1 amplicon 1, may be at risk for developing a lupus flare. Blood was sampled from stroke patients that received thrombectomy, including patients receiving tPA prior to thrombectomy. Sera from stroke patients will be compared with sera from controls for the amount of the AluYm1 amplicon 1. It is expected that compared to control samples, the sera from stroke patients will show an increase in the AluYm1 amplicon 1. DB1 / 151380125.4 23 NTR-016PC / 119601-5016 Example 8: Detection of NETs Biomarker in Serum for Prediction of Effective Dose Predose blood samples were collected in serum tubes from healthy adults and they are administered a single dose of NTR-441 at various doses. Post-dosing blood samples were collected in serum tubes. Sera were prepared and the AluYm1 amplicon 1 was quantified in all samples. Relative levels of serum AluYm1 amplicon 1 was plotted as a function of NTR- 441 dose. Serum AluYm1 amplicon 1, which are DNA fragments larger than mono- nucleosomes, reflect the degree of neutrophils undergoing NETosis. As shown in FIG.8A, the concentration of the AluYm1 amplicon Type B in the pool of all circulating DNA dose- dependently decreased in serum (detected by AluYm1 amplicon Type A) that was collected from healthy subjects after receiving a single dose of NTR-441. These results indicate that detection of the NETs biomarker in serum samples can be used for determining an effective dose of DNase therapy during Phase 1 studies in healthy subjects as well as in later stage clinical development in patients. Example 9: Further Development of Assay for the NETs Biomarker According to this disclosure, the disease specificity for the AluYm1 amplicon is determined, as well as its stability during active disease, and the threshold for the AluYm1 amplicon for a positive precision biomarker test in patients with active SLE. These studies identify in some embodiments the target population among SLE patients that will benefit from D1L3 therapy. To develop the AluYm1 amplicon as a precision biomarker, this disclosure provides three desirable performance parameters: (1) the threshold of the AluYm1 amplicon that determines positive precision biomarker test; (2) the stability of a positive the AluYm1 amplicon test during active SLE measured over time; and (3) the specificity of a positive biomarker test for SLE and other rheumatoid diseases. To determine the threshold for positive AluYm1 amplicon test, data will be collected using a validated procedure with specifications for inter, intra-, and operator-dependent assay variability that meet standards of Good Clinical Laboratory Practice (GCLP). The assay will first be validated as a qPCR protocol for the AluYm1 amplicon. The validated method will be used for an interim analysis of serum and plasma samples from 100 SLE DB1 / 151380125.4 24 NTR-016PC / 119601-5016 patients. The threshold for a positive test will be determined based on the mean concentration of the AluYm1 amplicon in SLE patients with inactive disease / in remission, defined per protocol as a sum of the clinical descriptor scores of the SLEDAI-2K lower than 6. Preliminary data from the AluYm1 amplicon in 12 patients was used to calculate the sample size that would be sufficient to identify the cut-off value for distinguishing active from inactive disease in SLE. A sample size of 21 in each group will have 90% power to detect a difference in means of -96.635 (the difference between a Group 1 mean, µ₁, of 23.615 and a Group 2 mean, µ₂, of 120.25) assuming that the common standard deviation is 92.03 using a two-group t-test with a 5% two-sided significance level. This exploratory statistical analysis ensures that the study will have the necessary statistical power to detect meaningful differences between the groups and provide reliable results to generate a robust cut-off value for the discrimination of the two groups. Considering additional covariates (such as age, gender, disease activity, and laboratory parameters of SLE disease), a larger sample size will be required to increase the robustness of the threshold determination to control for their effects and to assess the relationship between the biomarker and the SLEDAI-2K. The smaller sample size required for the AluYm1 amplicon suggests that it may be more sensitive biomarker than cell-free DNA in distinguishing between the two groups of active and inactive SLE to detect a difference in mean values. This potential sensitivity may indicate that the AluYm1 amplicon has a stronger and more distinct association with SLE disease activity. To achieve the second goal, the AluYm1 amplicon levels of individual patients at the initial and follow-up visit will be compared. It is estimated that the time between visits is approximately 1 to 12 weeks. This approach will determine whether the AluYm1 amplicon is permanently or temporarily elevated in SLE patients during active disease. A secondary objective is to determine whether an increase in the AluYm1 amplicon is specific to active SLE. Given observations of circulating DNA in patients with rheumatic disorders, it is expected that the AluYm1 amplicon is elevated in indications other than SLE. To demonstrate this experimentally, the observational study can enroll patients with rheumatoid arthritis, gout, and vasculitis during active disease and in remission. Taking into consideration a consistent biomarker variability and factoring in disease prevalence and heterogeneity, the study will involve a total sample size of 200 patients with rheumatoid DB1 / 151380125.4 25 NTR-016PC / 119601-5016 arthritis, 100 patients with gout, and 20 patients with vasculitis with the objective to distinguish between active and inactive disease states. If a selective elevation of the AluYm1 amplicon is detected during active disease, this approach will enable expansion of the precision therapy to other rheumatic diseases. The AluYm1 amplicon will be used to discriminate between patients with active (Clinical SLEDAI-2K score ≥ 6) and non-active SLE (clinical SLEDAI-2K score < 6). Optionally, healthy (non-SLE subjects can be used instead of inactive patients). To analyze the changes and stability of the biomarker over time a repeated measures ANOVA or a linear mixed-effects model, tailored for assessing data with multiple measurements will be taken from the same subjects across different time points. The statistical analysis will enable determination of significant differences in the biomarker’s means over time, offering insights into its trends and overall stability. These studies can provide a binary classifier (positive / negative) and enable enrollment criteria of SLE patients during an interventional trial with DNASE1L3 therapy, and can provide a pharmacodynamic endpoint. Characterization of the AluYm1 amplicon stability will determine a clinical development strategy for a precision therapy for SLE. A temporary elevation of the AluYm1 amplicon during active SLE will require a close monitoring of the AluYm1 amplicon (e.g., Point-of-Care testing) during clinical development, whereas a stable elevation of the AluYm1 amplicon during active SLE allows for testing of blood samples in a central laboratory. This disclosure further provides for optimizing the qPCR-based the AluYm1 amplicon assay for use as Point-of-Care Test. The initial process for measuring the AluYm1 amplicon requires up to five days from the time of collecting blood from a patient with active SLE until the test results become available to the treating physician, and the possibility for the patient to start with the targeted therapy. During this time, the blood is processed, frozen, and shipped on dry ice to a laboratory, where the DNA is isolated from blood samples (plasma / serum) and the AluYm1 amplicon is analyzed by qPCR. According to these subsequent studies, the time between blood sampling and receipt of test results is reduced. This can be important for effective therapy because a timely start of therapy reduces the DB1 / 151380125.4 26 NTR-016PC / 119601-5016 degree of organ damage caused by NETs. Further, a Point-of-Care test will be required for a precision therapy, if the AluYm1 amplicon is only temporarily elevated during active SLE. For example, the PCR equipment will be optimized with a mobile qPCR device as well as the assay protocol that enables performance of the assay at the point-of-care e.g., clinics, clinical trial sites, and mobile laboratories. In embodiments, the mobile qPCR unit weighs less than 5 lbs. compared to > 150 lbs. for typical benchtop qPCR. By transferring the qPCR protocol to this mobile device and then optimizing assay efficiency, a measure of how well the target DNA is amplified during each cycle of the PCR reaction can be determined. Efficiency will be calculated individually for reactions containing known concentrations of a standard, purified human genomic DNA (Promega, cat# G3041), across a 7-log concentration range. In preliminary studies, the AluYm1 amplicon mobile qPCR assay shows good linearity over a wide concentration range with assay efficiencies in the range of 80-90%. In silico analysis of the AluYm1 amplicon predicts GC content, melting temperature, and primer-dimer propensity that is favorable for qPCR. The specificity of the AluYm1 amplicon-mediated amplification was assessed via agarose gel electrophoresis observing a single band of the expected size, about 200 bp. Additional parameters affecting assay efficiency will be optimized, such as primer concentrations, different commercial sources of components for the qPCR reaction, reaction conditions (annealing temperature, extension time, cycling parameters), DNA extraction methods, purification steps, and storage conditions. Once assay efficiency is optimized for the mobile qPCR equipment, the limit of detection (LOD) and reproducibility will be characterized. In some embodiments, a direct qPCR method for the AluYm1 amplicon can be performed directly on patient samples (e.g., serum, plasma, urine, as well as others such as tear fluid, cerebral spinal fluid, and bronchoalveolar lavage fluid) without the need for DNA isolation. For example, a direct qPCR method can involve dilution of the sample along with tuning standard assay parameters for qPCR. Master mixes specifically designed to be used in direct qPCR applications are commercially available. In some aspects and embodiments, this disclosure provides a prototype of a lateral flow test (LFT) to enable at-home-testing for the AluYm1 amplicon. Based on their accurate, rapid readout and ease of home use, LFTs have been used for decades in the diagnostic field. DB1 / 151380125.4 27 NTR-016PC / 119601-5016 Most LFTs employ antibodies to specifically bind to an analyte of interest from a matrix (e.g., blood, urine, nasal secretions, etc.), complex it with a visualization macromolecule or particle (e.g., gold nanoparticles), and capture and concentrate the complex on a discrete region on the test strip, enabling a visual readout (i.e., the test line). Aside from the well- known commercialized LFTs (e.g., at-home pregnancy and drug tests, virus tests) there is a robust literature describing the utility of LFTs for the detection of nucleic acids in complex matrices. In some embodiments, an AluYm1 amplicon LFT employs venous blood, capillary blood, or urine. In some embodiments, the sample for LFT is capillary blood. Suitable lateral flow cartridges incorporate a cell-separator pad, capable of efficiently separating plasma from blood cells (FIG. 9A). In various embodiments, the LFT involves capture of the AluYm1 amplicon 1 directly from patient samples i.e., without an amplification step. Alternatively, capture of the biomarker can follow isothermal amplification. The direct capture of nucleic acids of interest from blood followed by lateral flow elucidation has been demonstrated for microRNAs. For example, direct capture can be accomplished using specialized peptide nucleic acids (PNA) which have an uncharged backbone of N-(2- aminoethyl)-glycine units linked by peptide bonds. This chemical property of PNAs promotes strand invasion of double-stranded nucleic acids via complementary sequence base pairing with a binding affinity far greater than standard DNA or RNA duplexes. In some embodiments, the LFT can employ ultra-bright gold nanoshell reporters (nanoComposix) to increase sensitivity and visualize the biomarker at the test line without instrumentation (FIG. 9B). Sequences from the AluYm1 amplicon will be used to design two PNA probes: (1) A 6-carboxyfluorescein (6FAM)-labelled PNA capture probe (using the AluYm1 amplicon forward primer sequence) to functionalize anti-FAM-coated gold nanoshells and bind to target sequence and (2) a biotin-labelled PNA sensing probe (using the AluYm1 amplicon reverse primer sequence) to concentrate the gold nanoshell complex on the test line. Synthetic double stranded DNA having the full consensus sequence used for the AluYm1 amplicon primer design has been produced to use as a standard to test this PNA-based LFT. Initial experiments will be conducted with this standard in physiological buffers with and without macromolecular crowding agents known to enhance lateral flow assays. Purified DB1 / 151380125.4 28 NTR-016PC / 119601-5016 genomic DNA will be used as a standard and determine the limit of visual detection (LOD) of the biomarker. If the sensitivity of the PNA-based direct approach is not sufficient or ideal to visualize the AluYm1 amplicon in human samples, an amplification step for the AluYm1 amplicon can be incorporated. Amplification can employ conventional PCR or isothermal amplification. In preliminary studies, conventional PCR was used to amplify and visualize the AluYm1 amplicon on AmpliDetect™ lateral flow cartridges (FIG.9C). Briefly, 6FAM- and biotin-labelled the AluYm1 amplicon forward and reverse primers, respectively, were used with Promega’s GoTaq™ Master Mix and human genomic DNA as template. The completed PCR reaction solution was diluted and mixed with nanoComposix anti-FAM functionalized gold nanoshells and applied to AmpliDetect™ lateral flow cartridges. We observed a prominent test line for PCR reaction solutions diluted up to a 1:100, demonstrating that labelled the AluYm1 amplicon primers are efficiently incorporated into the amplicon. This provided a strong proof-of-principle that the AluYm1 amplicon can be amplified using chemically end-labelled primers and labelled the AluYm1 amplicon amplification product visualized using a commercially available lateral flow strip without any specialized instrumentation. As the aforementioned amplification step requires a thermal cycler, and one goal is to provide a point-of-care or home-based diagnostic where such resources are unavailable, in some embodiments an amplification step is accomplished using isothermal amplification (e.g., using the recombinase polymerase amplification (RPA) system). RPA has been described in the literature and has been used in combination with LFT (RPA-LFT) for a number of diagnostic tests for the detection of nucleic acids in sample sources of all types. RPA-LFT can be configured to yield amplicons that are labelled with 6FAM and biotin and, therefore, can be elucidated on lateral flow cartridges. Primers used in conventional PCR can work in RPA-LFT. Using results for 6FAM- and biotin-labelled the AluYm1 amplicon primers in conventional PCR-LFT, primers can be optimized for RPA-LFT. In the majority of RPA-LFT applications an additional oligonucleotide, a “probe”, is required. As in the PNA-based direct approach, a limit of detection can be determined for the biomarker using both synthetic dsDNA target and purified genomic DNA. DB1 / 151380125.4 29 NTR-016PC / 119601-5016 The test can be validated in a clinical study in SLE patients and patients with other diseases. For example, patients would have a confirmed the AluYm1 amplicon test as assessed by the established conventional qPCR assay at the start of the study. the AluYm1 amplicon levels can be monitored every 3 days over 3 months to obtain clinical performance data of the LFT test. This study may enable detection of an early onset of disease flare, and enable start of treatment with a precision therapy to prevent disease progression and avoid use of very aggressive corticosteroid and other high dose immunosuppressive therapy during full disease flare ups. Other options for nanoparticles to potentially increase sensitivity include gold platinum nanoflowers and carbon nanoparticles. Other options for increasing sensitivity include use of fluorescent tags, some of which can be read by either small portable readers or even microscope lens-fitted smartphone cameras. Since the functional groups 6FAM and biotin exhibit exquisite equilibrium binding affinity, binding of the complexed analyte to the test line will be most affected by flow rates and mass transport considerations, parameters that are tunable by the screening of different nitrocellulose papers. Target abundance can be addressed by use of isothermal amplification schemes, but some techniques can suffer from non-specific amplification. Towards that end, the use of chemically modified oligonucleotide primers (e.g., PNAs) can be used to impart greater specificity. The use of blood as sample matrix could be less desirable in some embodiments (e.g., due to the need for cell separation, and the potential low abundance of the target in capillary blood). Since the biomarker is present in urine and there is precedence for LFT technology applied to elucidation of nucleic acids in urine, particularly for lupus patients with nephritis, use of urine for an LFT may be desirable in some embodiments. In some embodiments, combination of multiple biomarkers are used for SLE diagnosis and targeted treatment. For instance, treatments like anifrolumab have shown promise in clinical trials when administered to patients identified with specific Interferon (IFN) signatures, offering an encouraging precedent for biomarker-driven treatment strategies. Building on this DxTerity Diagnostics (Rancho Dominguez, CA) has developed DB1 / 151380125.4 30 NTR-016PC / 119601-5016 an IFN-1 gene signature test specifically designed for patients with SLE, aimed at identifying those at high risk for severe disease and less likely to respond to standard treatments. DB1 / 151380125.4 31 NTR-016PC / 119601-5016 SEQUENCES TARGET CONSENSUS SEQUENCES ALUSP Consensus Sequence (SEQ ID NO: 1): GGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGA TCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACT AAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAG GCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCG CCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAAAAAA AAAAAAAAAAAAA ALUYH3 Consensus Sequence (SEQ ID NO: 2): GGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCAGAGGCGGGCGGA TCATGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGCCTCTACTAA AAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGG CTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGC CACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAA AAAAAAAAAAA ALUYM1 Consensus Sequence (SEQ ID NO: 3): GGCCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGA TCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAA AAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGG CTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGC CACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAA AAAAAAAAAAA DB1 / 151380125.4 32 NTR-016PC / 119601-5016 L1M1 Consensus Sequence (SEQ ID NO: 4): ATGGCAGGAGTAAGTCCTTACTTATCAATAATAACATTGAATGTAAATGGACTAAACTCT CCAATCAAAAGACATAGAGTGGCTGAATGGATGAAAAAACAAGACCCANTGATCTGTTGC CTACAAGAAACACACTTCACCTATAAAGACACACATAGACTGAAAATAAAGGGATGGAAA AAGATATTCCATGCCAATGGAAACCAAAAAAGAGCAGGAGTAGCTATACTTATATCAGAC AAAATAGATTTCAAGACAAAAACTATAAGAAGAGACAAAGAAGGTCACTATATAATGATA AAGGGGTCAATTCAGCAAGAGGATATAACAATTNTAAATATATATGCACCCAACACTGGA GCACCCAGATATATAAAGCAAATATTATTAGAGCTAAAGAGAGAGATAGACCCCAATACA ATAATAGCTGGAGACTTCAACACCCCACTTTCAGCATTGGACAGATCTTCCAGACAGAAA ATCAACAAAGAAACATCGGACTTAATCTGCACTATAGACCAAATGGACCTAATAGATATT TACAGAACATTTCATCCAACGGCTGCAGAATACACATTCTTTTCCTCAGCACATGGATCA TTCTCAAGGATAGACCATATGTTAGGTCACAAAACAAGTCTTAAAACATTCAAAAAAATT GAAATAATATCAAGCATCTTCTCTGACCACAATGGAATAAAACTAGAAATCAATAACAAG AGGAATTTTGGAAACTATACAAACACATGGAAATTAAACAATATGCTCCTGAATGACCAG TGGGTCAATGAAGAAATTAAGAAGGAAATTGAAAAATTTCTTGAAACAAATGATAATGGA AACACAACATACCAAAACCTATGGGATACAGCAAAAGCAGTACTAAGAGGGAAGTTTATA GCTATAAGTGCCTACATCAAAAAAGAAGAAAAACTTCAAATAAACAACCTAACGATGCAT CTTAAAGAACTAGAAAAGCAAGAGCAAACCAAACCCAAAATTAGTAGAAGAAAAGAAATA ATAAAGATCAGAGCAGAAATAAATGAAATTGAAATGAAGAAAACAATACAAAAGATCAAT GAAACAAAAAGTTGGTTTTTTGAAAAGNTAAACAAAATTGACAAACCTTTAGCCAGACTA ANNAAGAAAAAAAGAGAGAAGACCCAAATAAATAAAATCAGAGATGAAAAAGGAGACATT ACAACTGATACCGCAGAAATTCAAAGGATCATTAGTGGCTACTATGAGCAACTATATGCC AATAAATTGGAAAATCTAGAAGAAATGGACAAATTCCTAGACACATACAACCTACCAAGA TTGAACCATGAAGAAATCCAAAACCTGAACAGACCAATAACAAGTAACGAGATCGAAGCC GTAATAAAAAGTCTCCCAGTAAAGAAAAGCCCGGGACCCGATGGCTTCACTGCTGAATTC TACCAAACATTTAAAGAAGAACTAATACCAATCCTACTCAAACTATTCCGAAAAATAGAG GAGGAGGGAATACTTCCAAACTCATTCTACGAGGCCAGTATTACCCTGATACCAAAACCA GACAAAGACACATCAAAAAAAGAAAACTACAGGCCAATATCTCTGATGAATATTGATGCA AAAATCCTCAACAAAATACTAGCAAACCGAATTCAACAATACATTAAAAAGATCATTCAT CATGACCAAGTGGGATTTATCCCNGGGATGCAAGGATGGTTCAACATACGCAAATCAATC AATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGAT DB1 / 151380125.4 33 NTR-016PC / 119601-5016 GCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACTG GGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAGT ATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGA TGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGA CAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTT GCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAA CTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCA TTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACA ATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTC TACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAA GATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAA GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC TATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTC TCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACATCA L1PB Consensus Sequence (SEQ ID NO: 5): ATGAATGGAATAGTACCTCACATCTCAATACTAACGTTGAATGTAAATGGCCTAAATGCT CCACTTAAAAGATACAGAATNGCAGAATGGATAAGAATTCACCAACCAAGTATCTGCTGC CTTCAAGAGACTCACCTAACACATAAGGACTCACATAAACTTAAGGTAAAGGGGTGGAAA DB1 / 151380125.4 34 NTR-016PC / 119601-5016 AAGACATTCCATGCAAATGGACACCAAAAGCGAGCAGGAGTAGCTATTCTTATATCAGAC AAAACAAACTTTAAAGCAACAGCAGTTAAAAAAGACAAAGAGGGACATTATATAATGATA AAAGGNCTNGTCCAACAGGAAAATATCACAATCCTAAATATATATGCACCTAACACTGGA GCTCCCAAATTTATAAAACAATTACTANTAGACCTAAGAAATGAGATAGACAGCAACACA ATAATAGTGGGGGACTTCAATACTCCACTGACAGCACTAGACAGGTCATCAAGACAGAAA GTCAACAAAGAAACAATGGACTTAAACTATACCCTGGAACAAATGGACTTAACAGATATT TACAGAACATTCTACCCAACAACCGCAGAATATACATTCTATTCANCAGCGCATGGAACN TTCTCCAAGATAGACCATATGATAGGCCACAAAACGAGCCTCAATAAATTTAAGAAAATC GAAATTATATCAAGCACTCTCTCAGACCACAGTGGAATAAAACTGGAAATCAACTCCAAA AGGAACCCTCAAAACCATGCAAATACATGGAAATTAAATAACCTGCTCCTGAATGATCAT TGGGTCAANAATGAAATCAAGATGGAAATTNAAAAATTCTTCGAACTGAACGACAATAGT GACACAACCTATCAAAACCTCTGGGATACAGCAAAGGCGGTGCTAAGAGGAAAGTTCATA GCCCTAAATGCCTACATCAAAAAGTCTGAAAGAGCACAAACAGACAATCTAAGGTCACAC CTCAAGGAACTAGAGAAACAAGAACAAACCAAACCCAAACCCAGCAGAAGAAAGGAAATA ACCAAGATCAGAGCAGAACTAAATGAAATTGAAACAAACAAAAAAATACAAAAGATAAAT GAAACAAAAAGCTGGTTCTTTGAAAAGATAAATAAAATTGATAGACCATTAGCGAGATTA ACCAAGAAAAGAAGAGAGAAGATCCAAATAAGCTCAATTAGAAACGAAACGGGAGATATT ACAACCGACACCACAGAAATACAAAAGATCATTCAAGGCTACTATGAACACCTTTACGCG CATAAACTAGAAAACCTAGAGGAGATGGATAAATTCCTGGAAANATACAACCCTCCTAGN TTAAATCAGGAAGAANTAGANACCCTGAACAGACCAATAACAAGCAGCGAGATTGAAATG GTAATTNAAAAATTACCAACAAAAAAAAGTCCAGGACCAGACGGATTCACAGCNGAATTC TACCAGACATTCAAAGAAGAATTGGTACCAATCCTATTGACACTATTCCACAAGATAGAG AAAGAGGGAATCCTCCCTAAATCATTCTATGAAGCCAGTATCACCCTAATACCAAAACCA GGAAAGGACATAACNAAAAAAGAAAACTACAGACCAATATCCCTGATGAACATAGATGCN AAAATCCTCAACAAAATACTAGCTAACCGAATCCAACAGCATATCAAAAAGATAATCCAC CATGATCAAGTGGGTTTCATACCAGGGATGCAGGGATGGTTTAACATACGCAAGTCAATA AATGTGATACACCACATAAACAGAATTAAAAACAAAAATCACATGATCATCTCAATAGAT GCAGAAAAAGCATTTGACAAAATCCAGCATCCCTTTATGATTAAAACCCTCAGCAAAATC GGCATANAAGGGACATACCTTAANGTAATAAAAGCCATCTATGACAAACCCACAGCCAAC ATNATACTGAATGGGGAAAAGTTGAAAGCATTCCCCCTGAGAACTGGAACAAGACAAGGA TGCCCACTCTCACCACTTCTNTTCAACATAGTACTGGAAGTCCTAGCCAGAGCAATCAGA CAAGAGAAAGAAATAAAGGGCATCCAAATCGGTAAAGAGGAAGTCAAACTGTCGCTGTTT DB1 / 151380125.4 35 NTR-016PC / 119601-5016 GCTGATGATATGATCGTNTACCTAGAAAACCCTAAAGACTCCTCCAGAAAGCTCCTAGAA CTGATAAANGAATTCAGCAAAGTTTCNGGATACAAAATTAATGTACACAAATCAGTAGCT CTNCTATACACCAACAGCGACCAAGCTGAGAATCAAATCAAGAACTCAACCCCTTTTACA ATAGCTGCAAAAAAAATAAAATACTTAGGAATATACCTAACCAAGGAGGTGAAAGACCTC TACAAGGAAAACTACAAAACACTGCTGAAAGAAATCATAGACGACACAAACAAATGGAAA CACATCCCATGCTCATGGATGGGTAGAATCAATATTGTGAAAATGACCATACTGCCAAAA GCAATCTACAAATTCAATGCAATTCCCATCAAAATACCACCATCATTCTTCACAGAACTA GAAAAAACAATCCTAAAATTCATATGGAACCAAAAAAGAGCCCGCATAGCCAAAGCAAGA CTAAGCAAAAAGAACAAATCTGGAGGCATCACATTACCCGACTTCAAACTATACTATAAG GCCATAGTCACCAAAACAGCATGGTACTGGTATAAAAATAGGCACATAGACCAATGGAAC AGAATAGAGAACCCAGAAATAAACCCAAATACTTACAGCCAACTGATCTTCGACAAAGCA AACAAAAACATAAAGTGGGGAAAGGACACCCTATTCAACAAATGGTGCTGGGATAATTGG CAAGCCACATGTAGGAGAATGAAACTGGATCCTCATCTCTCACCTTATACAAAAATCAAC TCAAGATGGATCAAGGACTTAAATCTAAGACCTGAAACCATAAAAATTCTAGAAGATAAC ATCGGAAAAACCCTTCTAGACATTGGCTTAGGCAAGGACTTCATGACCAAGAACCCAAAA GCAAATGCAACAAAAACAAAGATAAATAGNTGGGACTTAATTAAACTAAAGAGCTTCTGC ACGGCAAAAGGAACAGTCAGCAGAGTAAACAGACAACCCACAGAGTGGGAGAAAATCTTC ACAATCTATACATCTGACAAAGGACTAATATCCAGAATCTACAANGAACTCAAACAAATC AGCAAGAAAAAAACAAACAATCCCATCAAAAAGTGGGCTAAGGACATGAATAGACAATTC TCAAAAGAAGATATACAAATGGCCAACAAACATATGAAAAAATGCTCAACATCA L1P4 Consensus Sequence (SEQ ID NO: 6): ATGACAGGATCAAAACCTCACATATCAATATTAACCTTGAATGTAAATGGNCTAAACGCC CCACTTAAAAGGCACAGAGTGGCAAGTTGGATAAAAAAACAAGACCCANCCGTCTGCTGT CTTCAAGAGACCCATCTCACATGTAACGACACCCATAGGCTCAAAGTAAAGGGNTGGAGA AAGATCTATCACGCAAACGGAAAACAAAAAAGAGCAGGGGTCGCTATTCTTATATCAGAT AAAACAGACTTTAAACCAACAACAGTAAAAAAGGACAAAGAAGGGCATTACATAATGATA AAGGGTTCAATTCAACAAGAAGACTTAACTATCCTAAATATATACGCACCCAACATTGGA GCACCCAGATTCATAAAACAAGTNCTTCTAGACCTACGAAAAGACTTAGACAGCCACACA ATAATAGTGGGGGACTTCAACACCCCACTGACAGCGTTAGACAGATCATCGAGGCAGAAA DB1 / 151380125.4 36 NTR-016PC / 119601-5016 ACTAACAAAGAAATTCTGGACTTAAACTCGACACTTGACCAATTGGACCTAATAGACATC TACAGAATACTCCACCCANCAACCACAGAATATACATTCTTCTCATCTGCACACGGAACA TACTCTAAGATCGACCACATGCTCGGCCATAAAGCAAGTCTCAATAAATTCAAAAAAATC GAAATCATACCAACCATACTCTCGGACCACAGTGNAATAAAAATAGAAATCAATACCAAG AAGATCTCTCAAAACCACACAATTACATGGAAATTAAACAACTTGCTCCTGAATGACTTT TGGGTAAACAACGAAATTAAGGCAGAAATCAAAAAATTCTTTGAAATNAATGAAAACAGA GACACAACATACCAAAATCTCTGGGATGCAGCNAAAGCAGTGTTAAGAGGAAAGTTTATA GCGCTAAACGCCTACATCAAAAAGTTAGAAAGATCTCAAATTAACAATCTAACATCGCAC CTAGAGGAACTAGAAAAACAAGAACAAACCAACCCCAAAGCTAGCAGAAGAAAAGAAATA ACTAAAATCAGAGCAGAACTGAACGAAATTGAGACNCAAAAATCCATACAAAGGATCAAC GAAACCAAAAGTTGGTTCTTTGAAAGGATAAACAAGATCGATAGACCGCTAGCTAGATTA ACAAAGAAAAAAAGAGAGAAGATCCAAATAAGCACAATCAGAAATGACAAAGGTGACATT ACAACCGATCCCACAGAAATACAAAAGATCCTCAGAGACTATTATGAACACCTCTATGCA CACAAACTAGAAAATCTAGAGGAAATGGATAAATTCCTGGAAACACACAACCTCCCAAGA TTGAACCAGGAAGAAATTGAAACCCTGAACAGACCAATANCGAGTTCCGAAATTGAATCA GTAATAAAAAACCTACCAACCAAAAAAAGCCCCGGACCAGATGGATTCACAGCCGAATTC TACCAGACGTACAAAGAAGAGCTGGTACCAATCCTACTGAAACTATTCCAAAAAATCGAG GAGGAGGGACTCCTCCCTAACTCATTCTACGAAGCCAGCATCACCCTGATACCAAAACCT GGCAAAGACACAACGAAAAAAGAAAACTNCAGGCCAATATCCCTGATGAACATAGACGCA AAAATCCTCAACAAAATACTAGCAAACCGAATCCAGCAGCACATCAAAAAGTTAATTCAC CACGATCAAGTAGGCTTTATTCCTGGGATGCAAGGTTGGTTCAACATACGCAAATCAATA AATGTGATTCACCACATAAACAGAATTAAAAACAAAAACCATATGATCATCTCAATAGAC GCAGAAAAAGCTTTCGATAAAATCCAACATCCCTTCATGATAAAAACCCTCAACAAACTA GGCATCGAAGGAACATACCTCAAAATAATAAGAGCCATCTATGACAAACCCACAGCCAAC ATCATACTGAACGGGCAAAAGCTGGAAGCATTCCCCTTGAGAACTGGAACAAGACAAGGA TGCCCACTCTCACCACTCCTATTCAACATAGTACTGGAAGTCCTAGCCAGAGCAATCAGG CAAGAGAAAGAAATAAAAGGCATCCAAATAGGAAAAGAAGAAGTCAAACTATCTCTCTTC GCTGACGATATGATTCTATACCTAGAAAACCCTAAAGACTCCGCCAAAAGGCTCCTAGAA CTGATAAACGACTTCAGTAAAGTTTCAGGATACAAAATCAATGTACAAAAATCAGTAGCA TTTCTATACACCAATAACGTTCAAGCTGAGAGCCAAATCAAGAACGCAATCCCATTTACA ATAGCCACAAAAAAAATAAAATACCTAGGAATACATCTAACCAAGGAGGTGAAAGATCTC TACAAGGAGAACTACAAAACACTGCTGAAAGAAATCANAGATGACACAAACAAATGGAAA DB1 / 151380125.4 37 NTR-016PC / 119601-5016 AACATTCCATGCTCATGGATTGGAAGAATCAATATCGTTAAAATGGCCATACTGCCCAAA GCAATCTACAGATTCAACGCTATTCCTATCAAACTACCAACGTCATTTTTCACAGAATTA GAAAAAACTATTCTAAAATTCATATGGAACCAAAAAAGAGCCCGAATAGCCAAAGCAATC CTAAGCAAAAAGAACAAAGCCGGAGGCATCACATTACCCGACTTCAAACTATACTACAAG GCTACAGTAACCAAAACAGCATGGTACTGGTACAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAATAAAGCCGCACACCTACAACCATCTGATCTTCGACAAAGTC GACAAAAATAAGCAATGGGGAAAGGACTCCCTATTCAATAAATGGTGCTGGGATAACTGG CTAGCCATATGCAGAAGAATGAAACTGGACCCCTACCTTTCACCATATACAAAAATTAAC TCAAGATGGATTAAAGACTTAAATGTAAGACCTCAAACTATAAAAATCCTAGAAGAAAAC CTAGGAAATACCNTTCTGGACATCGGCCTTGGCAAAGAATTTATGACTAAGTCCTCAAAA GCAATTGCAACAAAAACAAAAATTGACAAGTGGGACCTAATTAAACTAAAGAGCTTCTGC ACAGCAAAAGAAACTATCAACAGAGTAAACAGACAACCTACAGAATGGGAGAAAATATTC GCAAACTATGCATCCGACAAAGGTCTAATATCCAGAATCTATAAGGAACTTAAACAANTC AACAAGCAAAAAACAAATAACCCCATTAAAAAGTGGGCAAAGGACATGAACAGACACTTC TCAAAAGAAGACATACAAGCGGCCAACAAACATATGAAAAAATGCTCAACATCA PRIMER SEQUENCES AluSp Primer Array TTTTGTATTTTTAGTAGAGACGGGGT (SEQ ID NO: 7) AGCCTGACCAACATGGAGAA (SEQ ID NO: 8) GGTCTCGAACTCCCGACC (SEQ ID NO: 9) CGGGCGGATCACCTGA (SEQ ID NO: 10) GCCTCGGCCTCCCAAA (SEQ ID NO: 11) ACGCCTGTAATCCCAGCA (SEQ ID NO: 12) TAGCCGGGCGTGGTG (SEQ ID NO: 13) TGGGATTACAGGCATGCG (SEQ ID NO: 14) GCTACTCGGGAGGCTGA (SEQ ID NO: 15) GGTTCAAGCGATTCTCCTGC (SEQ ID NO: 16) CGGGAGGCGGAGGT (SEQ ID NO: 17) TCTCGGCTCACCGCA (SEQ ID NO: 18) TCGCGCCATTGCACTC (SEQ ID NO: 19) DB1 / 151380125.4 38 NTR-016PC / 119601-5016 CTCTTGTTGCCCAGGCTG (SEQ ID NO: 20) GGCGCGGTGGCTC (SEQ ID NO: 21) TGCTGGGATTACAGGCGT (SEQ ID NO: 22) CTTTGGGAGGCCGAGG (SEQ ID NO: 23) TCAGGTGATCCGCCCG (SEQ ID NO: 24) GGTCGGGAGTTCGAGACC (SEQ ID NO: 25) TTCTCCATGTTGGTCAGGCT (SEQ ID NO: 26) ACCCCGTCTCTACTAAAAATACAAAA (SEQ ID NO: 27) ACCACGCCCGGCTA (SEQ ID NO: 28) CATGCCTGTAATCCCAGCTAC (SEQ ID NO: 29) CCTCAGCCTCCCGAGT (SEQ ID NO: 30) CAGGAGAATCGCTTGAACCC (SEQ ID NO: 31) GCAACCTCCGCCTCC (SEQ ID NO: 32) TGCGGTGAGCCGAGA (SEQ ID NO: 33) GAGTGCAATGGCGCGA (SEQ ID NO: 34) CAGCCTGGGCAACAAGAG (SEQ ID NO: 35) TTTTTTTTTTTTTGAGACGGAGTTTCG (SEQ ID NO: 36) AluY1m Primer Array TTTTTTTTTTGAGACGGAGTCTCG (SEQ ID NO: 37) AGCCTGGGCGACAGAG (SEQ ID NO: 38) CTCTGTCGCCCAGGCT (SEQ ID NO: 39) TCGCGCCACTGCACT (SEQ ID NO: 40) AGTGCAGTGGCGCGA (SEQ ID NO: 41) GCTTGCAGTGAGCCGAGA (SEQ ID NO: 42) TCTCGGCTCACTGCAAGC (SEQ ID NO: 43) TGAACCCGGGAGGCG (SEQ ID NO: 44) CGCCTCCCGGGTTCA (SEQ ID NO: 45) TGAGGCAGGAGAATGGCG (SEQ ID NO: 46) CGCCATTCTCCTGCCTC (SEQ ID NO: 47) DB1 / 151380125.4 39 NTR-016PC / 119601-5016 CAGCTACTCGGGAGGCT (SEQ ID NO: 48) GCCTCCCGAGTAGCTGG (SEQ ID NO: 49) GCGGGCGCCTGTAGTC (SEQ ID NO: 50) GACTACAGGCGCCCGC (SEQ ID NO: 51) AGCCGGGCGTGGTG (SEQ ID NO: 52) ACCACGCCCGGCT (SEQ ID NO: 53) CCCCGTCTCTACTAAAAATACAAAAAATT (SEQ ID NO: 54) AATTTTTTGTATTTTTAGTAGAGACGGGG (SEQ ID NO: 55) CCTGGCTAACACGGTGAAA (SEQ ID NO: 56) TTTCACCGTGTTAGCCAGG (SEQ ID NO: 57) GGTCAGGAGATCGAGACCAT (SEQ ID NO: 58) ATGGTCTCGATCTCCTGACC (SEQ ID NO: 59) GCGGGCGGATCACG (SEQ ID NO: 60) TCGTGATCCGCCCGC (SEQ ID NO: 61) CACTTTGGGAGGCCGAG (SEQ ID NO: 62) CTCGGCCTCCCAAAGTG (SEQ ID NO: 63) GCTCAAGCCTGTAATCCCAG (SEQ ID NO: 64) CTGGGATTACAGGCTTGAGC (SEQ ID NO: 65) CCGGGCGCGGTG (SEQ ID NO: 66) L1M1 Primer Array (61 Primer) ATGTTGAGCACCTTTTCATATGC (SEQ ID NO: 67) TTCTCAAAAGAAGACATACAAATGGC (SEQ ID NO: 68) ATGTCTATTCAGATCTTTTGCCCA (SEQ ID NO: 69) ATAGGAAAAAATCTAATAATCCGATTAAAAAATG (SEQ ID NO: 70) GAGTTGTTTGAGCTCCTTATATATTCTG (SEQ ID NO: 71) ACTACCCATCTGACAAGGGAT (SEQ ID NO: 72) TTGCAAATATTTTCTCCCATTCTGT (SEQ ID NO: 73) GAAACAATCAACAAAGTGAAGAGACA (SEQ ID NO: 74) CTTTGCTGTGCAGAAGCTTTT (SEQ ID NO: 75) DB1 / 151380125.4 40 NTR-016PC / 119601-5016 AGCAAAAATGGACAAATGGGATC (SEQ ID NO: 76) TTGGTTGCCTGTGCTTGT (SEQ ID NO: 77) GGTCTGGGCAAAGATTTCTTGA (SEQ ID NO: 78) CAATGTCCTGGAGAGTTTCCC (SEQ ID NO: 79) AACTATGAAACTACTACAAGAAAACATTGG (SEQ ID NO: 80) TGAGGTCTTAGATTTAAGTCTTTAATCCA (SEQ ID NO: 81) TCGCCATATACAAAAATCAAATCAAAATG (SEQ ID NO: 82) TTGTATATGGCGAGAGATAGGGG (SEQ ID NO: 83) ATATCCATATGCAGAAGAATGAAACTAGA (SEQ ID NO: 84) CCAGTTTTCCCAGCACCAT (SEQ ID NO: 85) TACACTGGGGAAAAGACAGTCT (SEQ ID NO: 86) TGTTCTTGGCACCTTTGTCG (SEQ ID NO: 87) AAATCCACACACCTACAGTGAAC (SEQ ID NO: 88) GTTTCTGGGTTCTCTATTCTGTTCC (SEQ ID NO: 89) GCATAAAAACAGACACATAGACCAAT (SEQ ID NO: 90) CAGTACCATGCTGTTTTGGTTAC (SEQ ID NO: 91) TGACTTCAAATTATACTACAGAGCTATAGT (SEQ ID NO: 92) CAGGTAATGTGATTCCTCCAGTT (SEQ ID NO: 93) CCAAAGCTATCCTGAGCAAAAAG (SEQ ID NO: 94) TATTCTGGGTCTTTTGTGGTTCC (SEQ ID NO: 95) CAGAAATAGAAAAAACAATCCTAAAATTTATATGG (SEQ ID NO: 96) TGAAGAATGTCATTGGTATTTTGATAGG (SEQ ID NO: 97) GCAATCTACAGATTCAATGCAATCC (SEQ ID NO: 98) TGCTTTGGGTAGTATGGACATTTTA (SEQ ID NO: 99) GTTCATGGATTGGAAGAATCAATATTGT (SEQ ID NO: 100) ATGGAATATCTTTCCATTTTTTGGTGT (SEQ ID NO: 101) AACACTGATGAAAGAAATTGAAGAGG (SEQ ID NO: 102) CATCAGTGTTTTATAGTTTTCATTGTAGAGA (SEQ ID NO: 103) DB1 / 151380125.4 41 NTR-016PC / 119601-5016 TTAACTTAACCAAAGAAGTGAAAGATCTC (SEQ ID NO: 104) TTCCTAGGTATTTAATTTTATTTGTGGCTA (SEQ ID NO: 105) ATCAAAAAAGTAATCCCATTTACAATAGC (SEQ ID NO: 106) GATTTCTTTTTCAGATTGTTCACTGTTG (SEQ ID NO: 107) CAAAAATCAGTAGCATTTCTATATGCCA (SEQ ID NO: 108) TATGTTGATTTTGTATCCTGCAACTT (SEQ ID NO: 109) ACTATTAGAACTGATAAACAAATTCAGTAAAG (SEQ ID NO: 110) GTGGAGTCTTTAGGTTTTTCCAAAT (SEQ ID NO: 111) CCTTGTTTGCAGATGATATGATCTTAT (SEQ ID NO: 112) ATAATTTGACTTCTTCCTTTCCAATTTG (SEQ ID NO: 113) GACAAGAGAAAGAAATAAAGGGCATC (SEQ ID NO: 114) GTCTGATTGCTCTAGCTAGGACT (SEQ ID NO: 115) TTTCACCACTGTTATTCAACATAGTACTGG (SEQ ID NO: 116) GTGGGCATCCTTGTCGTG (SEQ ID NO: 117) AAAACTGAAAGCCTTTCCTCTAAGA (SEQ ID NO: 118) AGTTTTTCCCCATTCAGTATGATACTAG (SEQ ID NO: 119) AAAAGCCATATACGACAGACCC (SEQ ID NO: 120) CTTTTATTATGTTGAGGTATGTTCCTTCTATA (SEQ ID NO: 121) TAAAAACCCTCAAAAAACTGGGTATAG (SEQ ID NO: 122) GGTTTTTATCATGAAGGGATGTTGAAT (SEQ ID NO: 123) CAATTGATGCTGAAAAAGCATTTGAT (SEQ ID NO: 124) GAAATGATCATATGGTTTTTGTCCTTCA (SEQ ID NO: 125) CAATGTGATACATCATATCAACAGAATGAA (SEQ ID NO: 126) TGATGTATCACATTGATTGATTTGCG (SEQ ID NO: 127) Type A AMPLICONS < 150 base pairs Assay 001 (SEQ ID NO: 128) TTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT DB1 / 151380125.4 42 NTR-016PC / 119601-5016 Assay 002(SEQ ID NO: 129) ATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCT CAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 003 (SEQ ID NO: 130) ATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 004 (SEQ ID NO: 131) ACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATA GGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 005 (SEQ ID NO: 132) ACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 006 (SEQ ID NO: 133) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTAC CCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 007 (SEQ ID NO: 134) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 008 (SEQ ID NO: 135) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAAC AATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 009 (SEQ ID NO: 136) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG DB1 / 151380125.4 43 NTR-016PC / 119601-5016 Assay 010 (SEQ ID NO: 137) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATG GACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 011 (SEQ ID NO: 138) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 012 (SEQ ID NO: 139) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAA AGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 013 (SEQ ID NO: 140) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 014 (SEQ ID NO: 141) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 015 (SEQ ID NO: 142) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTG Assay 016 (SEQ ID NO: 143) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 017 (SEQ ID NO: 144) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCA DB1 / 151380125.4 44 NTR-016PC / 119601-5016 Assay 018 (SEQ ID NO: 145) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCA Assay 019 (SEQ ID NO: 146) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 020 (SEQ ID NO: 147) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 021 (SEQ ID NO: 148) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 022 (SEQ ID NO: 148) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 023 (SEQ ID NO: 150) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Assay 024 (SEQ ID NO: 151) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA Assay 025 (SEQ ID NO: 152) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC DB1 / 151380125.4 45 NTR-016PC / 119601-5016 Assay 026 (SEQ ID NO: 153) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAAC Assay 027 (SEQ ID NO: 154) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 028 (SEQ ID NO: 155) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG Assay 029 (SEQ ID NO: 156) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Assay 030 (SEQ ID NO: 157) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG Assay 031 (SEQ ID NO: 158) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Assay 032 (SEQ ID NO: 159) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATA Assay 033 (SEQ ID NO: 160) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA DB1 / 151380125.4 46 NTR-016PC / 119601-5016 Assay 034 (SEQ ID NO: 161) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA Assay 035 (SEQ ID NO: 162) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Assay 036 (SEQ ID NO: 163) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCA Assay 037 (SEQ ID NO: 164) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Assay 038 (SEQ ID NO: 165) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCAT Assay 039 (SEQ ID NO: 166) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Assay 040 (SEQ ID NO: 167) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATG Assay 041 (SEQ ID NO: 168) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Assay 042 (SEQ ID NO: 169) DB1 / 151380125.4 47 NTR-016PC / 119601-5016 CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAA Assay 043 (SEQ ID NO: 170) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Assay 044 (SEQ ID NO: 171) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATC Assay 045 (SEQ ID NO: 172) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Assay 046 (SEQ ID NO: 173) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATA Assay 047 (SEQ ID NO: 174) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 048 (SEQ ID NO: 175) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCAC Assay 049 (SEQ ID NO: 176) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Assay 050 (SEQ ID NO: 177) DB1 / 151380125.4 48 NTR-016PC / 119601-5016 TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT Assay 051 (SEQ ID NO: 178) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Assay 052 (SEQ ID NO: 179) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGAC Assay 053 (SEQ ID NO: 180) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Assay 054 (SEQ ID NO: 181) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCAC Assay 055 (SEQ ID NO: 182) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCAC Assay 056 (SEQ ID NO: 183) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACT Assay 057 (SEQ ID NO: 184) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACT DB1 / 151380125.4 49 NTR-016PC / 119601-5016 Assay 058 (SEQ ID NO: 185) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAG Assay 059 (SEQ ID NO: 186) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAG Assay 060 (SEQ ID NO: 187) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACC Assay 061 (SEQ ID NO: 188) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACC Assay 062 (SEQ ID NO: 189) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTC Assay 063 (SEQ ID NO: 190) AGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 064 (SEQ ID NO: 191) TCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 065 (SEQ ID NO: 192) GCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCC GTCTCAAAAAAAAAA Assay 066 (SEQ ID NO: 193) DB1 / 151380125.4 50 NTR-016PC / 119601-5016 TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGG CGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 067 (SEQ ID NO: 194) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCC ACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAA Assay 068 (SEQ ID NO: 195) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT GAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAA AAAAAA Assay 069 (SEQ ID NO: 196) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGG GAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGC GAGACTCCGTCTCAAAAAAAAAA Assay 070 (SEQ ID NO: 197) TCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 071 (SEQ ID NO: 198) GCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 072 (SEQ ID NO: 199) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGG CGACAGAG Assay 073 (SEQ ID NO: 200) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCC ACTGCACTCCAGCCTGGGCGACAGAG DB1 / 151380125.4 51 NTR-016PC / 119601-5016 Assay 074 (SEQ ID NO: 201) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT GAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 075 (SEQ ID NO: 202) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGG GAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAG Assay 076 (SEQ ID NO: 203) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAA TGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGC CTGGGCGACAGAG Assay 077 (SEQ ID NO: 204) GCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 078 (SEQ ID NO: 205) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 079 (SEQ ID NO: 206) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCC ACTGCACT Assay 080 (SEQ ID NO: 207) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT GAGCCGAGATCGCGCCACTGCACT Assay 081 (SEQ ID NO: 208) DB1 / 151380125.4 52 NTR-016PC / 119601-5016 GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGG GAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 082 (SEQ ID NO: 209) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAA TGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACT Assay 083 (SEQ ID NO: 210) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT GAGCCGAGATCGCGCCACTGCACT Assay 084 (SEQ ID NO: 211) TGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Assay 085 (SEQ ID NO: 212) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA Assay 086 (SEQ ID NO: 213) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT GAGCCGAGA Assay 087 (SEQ ID NO: 214) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGG GAGGCGGAGCTTGCAGTGAGCCGAGA Assay 088 (SEQ ID NO: 215) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAA TGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGA DB1 / 151380125.4 53 NTR-016PC / 119601-5016 Assay 089 (SEQ ID NO: 216) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT GAGCCGAGA Assay 090 (SEQ ID NO: 217) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGG TGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCC GGGAGGCGGAGCTTGCAGTGAGCCGAGA Assay 091 (SEQ ID NO: 218) TGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 092 (SEQ ID NO: 219) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 093 (SEQ ID NO: 220) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGG GAGGCG Assay 094 (SEQ ID NO: 221) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAA TGGCGTGAACCCGGGAGGCG Assay 095 (SEQ ID NO: 222) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCG Assay 096 (SEQ ID NO: 223) DB1 / 151380125.4 54 NTR-016PC / 119601-5016 CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGG TGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCC GGGAGGCG Assay 097 (SEQ ID NO: 224) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATAC AAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGG CAGGAGAATGGCGTGAACCCGGGAGGCG Assay 098 (SEQ ID NO: 225) CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 099 (SEQ ID NO: 226) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 100 (SEQ ID NO: 227) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAA TGGCG Assay 101 (SEQ ID NO: 228) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 102 (SEQ ID NO: 229) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGG TGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 103 (SEQ ID NO: 230) DB1 / 151380125.4 55 NTR-016PC / 119601-5016 GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATAC AAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGG CAGGAGAATGGCG Assay 104 (SEQ ID NO: 231) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGT CTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTA CTCGGGAGGCTGAGGCAGGAGAATGGCG Assay 105 (SEQ ID NO: 232) GCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 106 (SEQ ID NO: 233) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 107 (SEQ ID NO: 234) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCC CAGCTACTCGGGAGGC Assay 108 (SEQ ID NO: 235) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGG TGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 109 (SEQ ID NO: 236) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATAC AAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC Assay 110 (SEQ ID NO: 237) DB1 / 151380125.4 56 NTR-016PC / 119601-5016 GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGT CTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTA CTCGGGAGGC Assay 111 (SEQ ID NO: 238) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTA ACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGC GCCTGTAGTCCCAGCTACTCGGGAGGC Assay 112 (SEQ ID NO: 239) AGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Assay 113 (SEQ ID NO: 240) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Assay 114 (SEQ ID NO: 241) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGG TGGCGGGCGCCTGTAGTC Assay 115 (SEQ ID NO: 242) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATAC AAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Assay 116 (SEQ ID NO: 243) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGT CTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Assay 117 (SEQ ID NO: 244) DB1 / 151380125.4 57 NTR-016PC / 119601-5016 CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTA ACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGC GCCTGTAGTC Assay 118 (SEQ ID NO: 245) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGA GATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT AGCCGGGCGTGGTGGCGGGCGCCTGTAGTC Assay 119 (SEQ ID NO: 246) CCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 120 (SEQ ID NO: 247) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGG T Assay 121 (SEQ ID NO: 248) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATAC AAAAAATTAGCCGGGCGTGGT Assay 122 (SEQ ID NO: 249) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGT CTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 123 (SEQ ID NO: 250) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTA ACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGT Assay 124 (SEQ ID NO: 251) DB1 / 151380125.4 58 NTR-016PC / 119601-5016 GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGA GATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT AGCCGGGCGTGGT Assay 125 (SEQ ID NO: 252) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATC ACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAA ATACAAAAAATTAGCCGGGCGTGGT Assay 126 (SEQ ID NO: 253) CCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 127 (SEQ ID NO: 254) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATAC AAAAAATT Assay 128 (SEQ ID NO: 255) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGT CTCTACTAAAAATACAAAAAATT Assay 129 (SEQ ID NO: 256) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTA ACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 130 (SEQ ID NO: 257) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGA GATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATT Assay 131 (SEQ ID NO: 258) DB1 / 151380125.4 59 NTR-016PC / 119601-5016 CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATC ACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAA ATACAAAAAATT Assay 132 (SEQ ID NO: 259) GGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 133 (SEQ ID NO: 260) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 134 (SEQ ID NO: 261) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTA ACACGGTGAAA Assay 135 (SEQ ID NO: 262) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGA GATCGAGACCATCCTGGCTAACACGGTGAAA Assay 136 (SEQ ID NO: 263) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATC ACGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAA Assay 137 (SEQ ID NO: 264) GCGGGCGGATCACGAGGTCAGGAGATCGAGACCAT Assay 138 (SEQ ID NO: 265) CACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCAT Assay 139 (SEQ ID NO: 266) DB1 / 151380125.4 60 NTR-016PC / 119601-5016 GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGA GATCGAGACCAT Assay 140 (SEQ ID NO: 267) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATC ACGAGGTCAGGAGATCGAGACCAT Assay 141 (SEQ ID NO: 268) CACTTTGGGAGGCCGAGGCGGGCGGATCACGA Assay 142 (SEQ ID NO: 269) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGA Assay 143 (SEQ ID NO: 270) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATC ACGA Assay 144 (SEQ ID NO: 271) GCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAG Assay 145 (SEQ ID NO: 272) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAGCACTTTGGGAGGCCGAG Assay 146 (SEQ ID NO: 273) CCGGGCGCGGTGGCTCAAGCCTGTAATCCCAG Assay 147 (SEQ ID NO: 274) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA DB1 / 151380125.4 61 NTR-016PC / 119601-5016 Assay 148 (SEQ ID NO: 275) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCG TCTCTACTAAAAATACAAAA Assay 149 (SEQ ID NO: 276) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGT TCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Assay 150 (SEQ ID NO: 277) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACC TGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAA TACAAAA Assay 151 (SEQ ID NO: 278) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCA ACATGGAGAAACCCCGTCTCTACTAAAAATACAAAA Assay 152 (SEQ ID NO: 279) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATAC AAAA Assay 153 (SEQ ID NO: 280) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACC Assay 154 (SEQ ID NO: 281) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGT TCGAGACC Assay 155 (SEQ ID NO: 282) DB1 / 151380125.4 62 NTR-016PC / 119601-5016 GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACC TGAGGTCGGGAGTTCGAGACC Assay 156 (SEQ ID NO: 283) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACC Assay 157 (SEQ ID NO: 284) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGC Assay 158 (SEQ ID NO: 285) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGC Assay 159 (SEQ ID NO: 286) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTG GTGGCGCATGCCTGTAATCCCA Assay 160 (SEQ ID NO: 287) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCG TCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 161 (SEQ ID NO: 288) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGT TCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGC CGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 162 (SEQ ID NO: 289) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 163 (SEQ ID NO: 290) DB1 / 151380125.4 63 NTR-016PC / 119601-5016 CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCA ACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATG CCTGTAATCCCA Assay 164 (SEQ ID NO: 291) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATAC AAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCA Assay 165 (SEQ ID NO: 292) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCC CA Assay 166 (SEQ ID NO: 293) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTG GTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 167 (SEQ ID NO: 294) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGA ATCGCTTGAACC Assay 168 (SEQ ID NO: 295) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 169 (SEQ ID NO: 296) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATAC AAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGC AGGAGAATCGCTTGAACC Assay 170 (SEQ ID NO: 297) DB1 / 151380125.4 64 NTR-016PC / 119601-5016 ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 171 (SEQ ID NO: 298) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC Assay 172 (SEQ ID NO: 299) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTG GTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC CGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 173 (SEQ ID NO: 300) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGA ATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 174 (SEQ ID NO: 301) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGA GCCGAGA Assay 175 (SEQ ID NO: 302) CGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 176 (SEQ ID NO: 303) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGT GAGCCGAGA Assay 177 (SEQ ID NO: 304) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAG GCGGAGGTTGCGGTGAGCCGAGA DB1 / 151380125.4 65 NTR-016PC / 119601-5016 Assay 178 (SEQ ID NO: 305) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGA Assay 179 (SEQ ID NO: 306) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGA ATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAG CCTGGGCAACAAGAG Assay 180 (SEQ ID NO: 307) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGA GCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 181 (SEQ ID NO: 308) CGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAA GAG Assay 182 (SEQ ID NO: 309) TCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 183 (SEQ ID NO: 310) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAG GCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 184 (SEQ ID NO: 311) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGC ACTCCAGCCTGGGCAACAAGAG Assay 185 (SEQ ID NO: 312) DB1 / 151380125.4 66 NTR-016PC / 119601-5016 TGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAG Assay 186 (SEQ ID NO: 313) GGCGCGGTGGCTCACGCCTGTAATCCCAGCA Assay 187 (SEQ ID NO: 314) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGA Assay 188 (SEQ ID NO: 315) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACC TGA Assay 189 (SEQ ID NO: 316) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGA Assay 190 (SEQ ID NO: 317) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Assay 191 (SEQ ID NO: 318) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGT TCGAGACCAGCCTGACCAACATGGAGAA Assay 192 (SEQ ID NO: 319) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACC TGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Assay 193 (SEQ ID NO: 320) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCA ACATGGAGAA DB1 / 151380125.4 67 NTR-016PC / 119601-5016 Assay 194 (SEQ ID NO: 321) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA Assay 195 (SEQ ID NO: 322) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTG GT Assay 196 (SEQ ID NO: 323) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCG TCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Assay 197 (SEQ ID NO: 324) ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGT TCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGC CGGGCGTGGT Assay 198 (SEQ ID NO: 325) GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACC TGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAA TACAAAANTTAGCCGGGCGTGGT Assay 199 (SEQ ID NO: 326) CTTTGGGAGGCCGAGGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCA ACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Assay 200 (SEQ ID NO: 327) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATAC AAAANTTAGCCGGGCGTGGT DB1 / 151380125.4 68 NTR-016PC / 119601-5016 Assay 201 (SEQ ID NO: 328) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGT Assay 202 (SEQ ID NO: 329) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTG GTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Assay 203 (SEQ ID NO: 330) CGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCG TCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTA CTCGGGAGGCTGAGG Assay 204 (SEQ ID NO: 331) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Assay 205 (SEQ ID NO: 332) GGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATAC AAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Assay 206 (SEQ ID NO: 333) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCC CAGCTACTCGGGAGGCTGAGG Assay 207 (SEQ ID NO: 334) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG Assay 208 (SEQ ID NO: 335) AGCCTGACCAACATGGAGAAACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTG GTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACC CGGGAGGCGGAGGTTGC DB1 / 151380125.4 69 NTR-016PC / 119601-5016 Assay 209 (SEQ ID NO: 336) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGA ATCGCTTGAACCCGGGAGGCGGAGGTTGC Assay 210 (SEQ ID NO: 337) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Assay 211 (SEQ ID NO: 338) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Assay 212 (SEQ ID NO: 339) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAG GCGGAGGTTGC Assay 213 (SEQ ID NO: 340) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGC Assay 214 (SEQ ID NO: 341) TAGCCGGGCGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGA ATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 215 (SEQ ID NO: 342) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGA GCCGAGATCGCGCCATTGCACTC Assay 216 (SEQ ID NO: 343) CGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC DB1 / 151380125.4 70 NTR-016PC / 119601-5016 Assay 217 (SEQ ID NO: 344) ACCCCGTCTCTACTAAAAATACAAAANTTAGCCGGGCGTGGTGGCGCATGCCTGTAATCC CAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGT GAGCCGAGATCGCGCCATTGCACTC Assay 218 (SEQ ID NO: 345) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAG GCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 219 (SEQ ID NO: 346) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGC ACTC Assay 220 (SEQ ID NO: 347) TGCGGTGAGCCGAGATCGCGCCATTGCACTC Assay 221 (SEQ ID NO: 348) GCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGA GCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAA AAAAAAAA Assay 222 (SEQ ID NO: 349) CGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAA GAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 223 (SEQ ID NO: 350) TCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAA A DB1 / 151380125.4 71 NTR-016PC / 119601-5016 Assay 224 (SEQ ID NO: 351) CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAG GCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGA AACTCCGTCTCAAAAAAAAAAAAA Assay 225 (SEQ ID NO: 352) CAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGC ACTCCAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Assay 226 (SEQ ID NO: 353) TGCGGTGAGCCGAGATCGCGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCGT CTCAAAAAAAAAAAAA Assay 227 (SEQ ID NO: 354) CAGCCTGGGCAACAAGAGCGAAACTCCGTCTCAAAAAAAAAAAAA Type B AMPLICONS > 150 base pairs Assay 228 (SEQ ID NO: 355) ACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATA GGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAA AAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 229 (SEQ ID NO: 356) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTAC CCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAA AAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAA GACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 230 (SEQ ID NO: 357) DB1 / 151380125.4 72 NTR-016PC / 119601-5016 AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAAC AATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATC TGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATC TAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACAT ACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 231 (SEQ ID NO: 358) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATG GACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAA GTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGA TTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCG ATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCA AACAGGCATATGAAAAGGTGCTCAACAT Assay 232 (SEQ ID NO: 359) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAA AGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGA TCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACA ACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAG AATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATG GGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATAT GAAAAGGTGCTCAACAT Assay 233 (SEQ ID NO: 360) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGAT TTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCAC ATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCC ACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATA TATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCA AAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAA AGGTGCTCAACAT Assay 234 (SEQ ID NO: 361) DB1 / 151380125.4 73 NTR-016PC / 119601-5016 ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC TATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTC TCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 235 (SEQ ID NO: 362) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACC CATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAA AATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAG ACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 236 (SEQ ID NO: 363) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAA AATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAA CAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAA GGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAA TCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAAT GGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 237 (SEQ ID NO: 364) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA DB1 / 151380125.4 74 NTR-016PC / 119601-5016 CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAAT AACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAA AAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAG GCATATGAAAAGGTGCTCAACAT Assay 238 (SEQ ID NO: 365) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGA TTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCA CATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACC CACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAAT ATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGC AAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAA AAGGTGCTCAACAT Assay 239 (SEQ ID NO: 365) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTA ATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAA AAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGG AGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGC TCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGA ATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAA CAT DB1 / 151380125.4 75 NTR-016PC / 119601-5016 Assay 240 (SEQ ID NO: 367) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATA GACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 241 (SEQ ID NO: 368) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC TATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTC TCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 242 (SEQ ID NO: 369) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA DB1 / 151380125.4 76 NTR-016PC / 119601-5016 CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACC CATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAA AATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAG ACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 243 (SEQ ID NO: 370) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGA CAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAA TAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACA AATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 244 (SEQ ID NO: 371) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA DB1 / 151380125.4 77 NTR-016PC / 119601-5016 CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGG GCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAAT GGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGA GACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAA CCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAA AATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGC ATATGAAAAGGTGCTCAACAT Assay 245 (SEQ ID NO: 372) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAA GATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGAT CACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAA CCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGA ATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGG GCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATG AAAAGGTGCTCAACAT Assay 246 (SEQ ID NO: 373) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA DB1 / 151380125.4 78 NTR-016PC / 119601-5016 ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTG AGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAG TTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAA TGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAG GAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGAT CTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGC TCAACAT Assay 247 (SEQ ID NO: 374) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAA TACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAA AAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGA GAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCT CAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAA TAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAAC AT Assay 248 (SEQ ID NO: 375) DB1 / 151380125.4 79 NTR-016PC / 119601-5016 CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATA GACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 249 (SEQ ID NO: 376) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCAC AAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCT DB1 / 151380125.4 80 NTR-016PC / 119601-5016 GCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATAT TTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAAC TCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATT TCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 250 (SEQ ID NO: 377) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG AAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGG CAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAA AGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACT ACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGA AAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAG AAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 251 (SEQ ID NO: 378) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG DB1 / 151380125.4 81 NTR-016PC / 119601-5016 GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGA CAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAA TAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACA AATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 252 (SEQ ID NO: 379) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAAT AACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAA DB1 / 151380125.4 82 NTR-016PC / 119601-5016 AAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAG GCATATGAAAAGGTGCTCAACAT Assay 253 (SEQ ID NO: 380) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATT TCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACA TCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCA CAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATAT ATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAA AAGATCTGAATAGACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAA GGTGCTCAACAT Assay 254 (SEQ ID NO: 381) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT DB1 / 151380125.4 83 NTR-016PC / 119601-5016 CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATA GACATTTCTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 255 (SEQ ID NO: 382) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA DB1 / 151380125.4 84 NTR-016PC / 119601-5016 ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACA AGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTG CACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATT TGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACT CTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACATTT CTCAAAAGAAGACATACAAATGGCAAACAGGCATATGAAAAGGTGCTCAACAT Assay 256 (SEQ ID NO: 383) GAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTAC CCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAA AAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 257 (SEQ ID NO: 384) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAAC AATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATC TGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATC TAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 258 (SEQ ID NO: 385) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATG GACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAA GTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGA TTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCG ATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 259 (SEQ ID NO: 386) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAA AGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGA TCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACA ACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAG AATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATG GGCAAAAGATCTGAATAGACAT DB1 / 151380125.4 85 NTR-016PC / 119601-5016 Assay 260 (SEQ ID NO: 387) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGAT TTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCAC ATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCC ACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATA TATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCA AAAGATCTGAATAGACAT Assay 261 (SEQ ID NO: 388) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC TATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 262 (SEQ ID NO: 389) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACC CATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAA AATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 263 (SEQ ID NO: 390) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAA AATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAA CAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAA DB1 / 151380125.4 86 NTR-016PC / 119601-5016 GGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAA TCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 264 (SEQ ID NO: 391) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAAT AACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAA AAAATGGGCAAAAGATCTGAATAGACAT Assay 265 (SEQ ID NO: 392) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGA TTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCA CATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACC CACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAAT ATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGC AAAAGATCTGAATAGACAT Assay 266 (SEQ ID NO: 393) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTA DB1 / 151380125.4 87 NTR-016PC / 119601-5016 ATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAA AAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGG AGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGC TCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGA ATAGACAT Assay 267 (SEQ ID NO: 394) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATA GACAT Assay 268 (SEQ ID NO: 395) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC TATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 269 (SEQ ID NO: 396) DB1 / 151380125.4 88 NTR-016PC / 119601-5016 GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACC CATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAA AATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 270 (SEQ ID NO: 397) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGA CAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAA TAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 271 (SEQ ID NO: 398) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA DB1 / 151380125.4 89 NTR-016PC / 119601-5016 CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGG GCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAAT GGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGA GACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAA CCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAA AATGGGCAAAAGATCTGAATAGACAT Assay 272 (SEQ ID NO: 399) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAA GATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGAT CACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAA CCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGA ATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGG GCAAAAGATCTGAATAGACAT Assay 273 (SEQ ID NO: 400) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA DB1 / 151380125.4 90 NTR-016PC / 119601-5016 ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTG AGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAG TTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAA TGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAG GAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGAT CTGAATAGACAT Assay 274 (SEQ ID NO: 401) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAA TACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAA AAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGA GAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCT CAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAA TAGACAT Assay 275 (SEQ ID NO: 402) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC DB1 / 151380125.4 91 NTR-016PC / 119601-5016 CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATA GACAT Assay 276 (SEQ ID NO: 403) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCAC AAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCT GCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATAT TTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAAC TCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT DB1 / 151380125.4 92 NTR-016PC / 119601-5016 Assay 277 (SEQ ID NO: 404) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG AAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGG CAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAA AGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACT ACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGA AAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 278 (SEQ ID NO: 405) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA DB1 / 151380125.4 93 NTR-016PC / 119601-5016 AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGA CAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAA TAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT Assay 279 (SEQ ID NO: 406) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAAT AACCAGAATATATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAA AAAATGGGCAAAAGATCTGAATAGACAT Assay 280 (SEQ ID NO: 407) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA DB1 / 151380125.4 94 NTR-016PC / 119601-5016 GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATT TCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACA TCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCA CAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATAT ATAAGGAGCTCAAACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAA AAGATCTGAATAGACAT Assay 281 (SEQ ID NO: 408) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC DB1 / 151380125.4 95 NTR-016PC / 119601-5016 AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTCTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATA GACAT Assay 282 (SEQ ID NO: 409) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACA AGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTG CACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATT TGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACT CTATAGGAAAAAATCTAATAATCCGATTAAAAAATGGGCAAAAGATCTGAATAGACAT DB1 / 151380125.4 96 NTR-016PC / 119601-5016 Assay 283 (SEQ ID NO: 410) AGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAAC AATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATC TGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 284 (SEQ ID NO: 411) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATG GACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAA GTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGA TTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 285 (SEQ ID NO: 412) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAA AGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGA TCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACA ACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAG AATATATAAGGAGCTCAAACAACTC Assay 286 (SEQ ID NO: 413) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGAT TTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCAC ATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCC ACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATA TATAAGGAGCTCAAACAACTC Assay 287 (SEQ ID NO: 414) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC DB1 / 151380125.4 97 NTR-016PC / 119601-5016 Assay 288 (SEQ ID NO: 415) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACC CATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 289 (SEQ ID NO: 416) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAA AATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAA CAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAA GGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 290 (SEQ ID NO: 417) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAAT AACCAGAATATATAAGGAGCTCAAACAACTC Assay 291 (SEQ ID NO: 418) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC DB1 / 151380125.4 98 NTR-016PC / 119601-5016 TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGA TTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCA CATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACC CACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAAT ATATAAGGAGCTCAAACAACTC Assay 292 (SEQ ID NO: 419) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTA ATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAA AAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGG AGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGC TCAAACAACTC Assay 293 (SEQ ID NO: 420) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTC Assay 294 (SEQ ID NO: 421) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC DB1 / 151380125.4 99 NTR-016PC / 119601-5016 CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 295 (SEQ ID NO: 422) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACC CATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 296 (SEQ ID NO: 423) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC DB1 / 151380125.4 100 NTR-016PC / 119601-5016 AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGA CAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 297 (SEQ ID NO: 424) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGG GCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAAT GGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGA GACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAA CCAGAATATATAAGGAGCTCAAACAACTC Assay 298 (SEQ ID NO: 425) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAA GATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGAT CACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAA CCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGA ATATATAAGGAGCTCAAACAACTC DB1 / 151380125.4 101 NTR-016PC / 119601-5016 Assay 299 (SEQ ID NO: 426) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTG AGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAG TTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAA TGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAG GAGCTCAAACAACTC Assay 300 (SEQ ID NO: 427) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAA TACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAA AAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGA DB1 / 151380125.4 102 NTR-016PC / 119601-5016 GAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCT CAAACAACTC Assay 301 (SEQ ID NO: 428) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTC Assay 302 (SEQ ID NO: 429) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT DB1 / 151380125.4 103 NTR-016PC / 119601-5016 GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCAC AAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCT GCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATAT TTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAAC TC Assay 303 (SEQ ID NO: 430) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG AAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGG CAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAA AGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACT ACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 304 (SEQ ID NO: 431) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA DB1 / 151380125.4 104 NTR-016PC / 119601-5016 AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGA CAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACTC Assay 305 (SEQ ID NO: 432) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAAT AACCAGAATATATAAGGAGCTCAAACAACTC DB1 / 151380125.4 105 NTR-016PC / 119601-5016 Assay 306 (SEQ ID NO: 433) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATT TCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACA TCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCA CAGAATGGGAGAAAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATAT ATAAGGAGCTCAAACAACTC Assay 307 (SEQ ID NO: 434) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA DB1 / 151380125.4 106 NTR-016PC / 119601-5016 AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCA AACAACTC Assay 308 (SEQ ID NO: 435) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACA AGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTG CACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATT TGCAAACTACCCATCTGACAAGGGATTAATAACCAGAATATATAAGGAGCTCAAACAACT C DB1 / 151380125.4 107 NTR-016PC / 119601-5016 Assay 309 (SEQ ID NO: 436) GGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATG GACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAA GTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 310 (SEQ ID NO: 437) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAA AGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGA TCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACA ACCCACAGAATGGGAGAAAATATTTGCAA Assay 311 (SEQ ID NO: 438) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGAT TTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCAC ATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCC ACAGAATGGGAGAAAATATTTGCAA Assay 312 (SEQ ID NO: 439) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAA Assay 313 (SEQ ID NO: 440) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA DB1 / 151380125.4 108 NTR-016PC / 119601-5016 Assay 314 (SEQ ID NO: 441) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAA AATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAA CAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 315 (SEQ ID NO: 442) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 316 (SEQ ID NO: 443) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGA TTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCA CATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACC CACAGAATGGGAGAAAATATTTGCAA Assay 317 (SEQ ID NO: 444) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA DB1 / 151380125.4 109 NTR-016PC / 119601-5016 CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTA ATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAA AAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGG AGAAAATATTTGCAA Assay 318 (SEQ ID NO: 445) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAA Assay 319 (SEQ ID NO: 446) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTT GCAA Assay 320 (SEQ ID NO: 447) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA DB1 / 151380125.4 110 NTR-016PC / 119601-5016 TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGG AAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 321 (SEQ ID NO: 448) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 322 (SEQ ID NO: 449) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGG DB1 / 151380125.4 111 NTR-016PC / 119601-5016 GCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAAT GGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGA GACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 323 (SEQ ID NO: 450) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAA GATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGAT CACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAA CCCACAGAATGGGAGAAAATATTTGCAA Assay 324 (SEQ ID NO: 451) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTG AGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAG TTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAA TGGGAGAAAATATTTGCAA DB1 / 151380125.4 112 NTR-016PC / 119601-5016 Assay 325 (SEQ ID NO: 452) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAA TACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAA AAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGA GAAAATATTTGCAA Assay 326 (SEQ ID NO: 453) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA DB1 / 151380125.4 113 NTR-016PC / 119601-5016 GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAA Assay 327 (SEQ ID NO: 454) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCAC AAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCT GCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATAT TTGCAA Assay 328 (SEQ ID NO: 455) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA DB1 / 151380125.4 114 NTR-016PC / 119601-5016 ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG AAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGG CAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAA AGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 329 (SEQ ID NO: 456) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAAT CAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 330 (SEQ ID NO: 457) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA DB1 / 151380125.4 115 NTR-016PC / 119601-5016 AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAA GAGACAACCCACAGAATGGGAGAAAATATTTGCAA Assay 331 (SEQ ID NO: 458) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATT TCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACA TCAAGTTAAAAAGCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCA CAGAATGGGAGAAAATATTTGCAA DB1 / 151380125.4 116 NTR-016PC / 119601-5016 Assay 332 (SEQ ID NO: 459) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGA AAATATTTGCAA Assay 333 (SEQ ID NO: 460) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT DB1 / 151380125.4 117 NTR-016PC / 119601-5016 AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACA AGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTG CACAGCAAAGGAAACAATCAACAAAGTGAAGAGACAACCCACAGAATGGGAGAAAATATT TGCAA Assay 334 (SEQ ID NO: 461) AACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAA AGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGA TCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 335 (SEQ ID NO: 462) TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGAT TTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCAC ATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 336 (SEQ ID NO: 463) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAG Assay 337 (SEQ ID NO: 464) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA DB1 / 151380125.4 118 NTR-016PC / 119601-5016 CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 338 (SEQ ID NO: 465) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAA AATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 339 (SEQ ID NO: 466) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 340 (SEQ ID NO: 467) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGA TTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCA CATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 341 (SEQ ID NO: 468) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT DB1 / 151380125.4 119 NTR-016PC / 119601-5016 GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTA ATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAA AAAGCTTCTGCACAGCAAAG Assay 342 (SEQ ID NO: 469) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAG Assay 343 (SEQ ID NO: 470) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGC ACAGCAAAG Assay 344 (SEQ ID NO: 471) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA DB1 / 151380125.4 120 NTR-016PC / 119601-5016 CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 345 (SEQ ID NO: 472) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 346 (SEQ ID NO: 473) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGG GCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAAT GGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG DB1 / 151380125.4 121 NTR-016PC / 119601-5016 Assay 347 (SEQ ID NO: 474) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAA GATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGAT CACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 348 (SEQ ID NO: 475) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTG AGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAG TTAAAAAGCTTCTGCACAGCAAAG Assay 349 (SEQ ID NO: 476) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT DB1 / 151380125.4 122 NTR-016PC / 119601-5016 GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAA TACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAA AAGCTTCTGCACAGCAAAG Assay 350 (SEQ ID NO: 477) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAG Assay 351 (SEQ ID NO: 478) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA DB1 / 151380125.4 123 NTR-016PC / 119601-5016 CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCAC AAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCT GCACAGCAAAG Assay 352 (SEQ ID NO: 479) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG AAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGG CAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAA AG Assay 353 (SEQ ID NO: 480) DB1 / 151380125.4 124 NTR-016PC / 119601-5016 AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGC AAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 354 (SEQ ID NO: 481) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT DB1 / 151380125.4 125 NTR-016PC / 119601-5016 GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAA ATGGGATCACATCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 355 (SEQ ID NO: 482) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATT TCTTGAGTAATACCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACA TCAAGTTAAAAAGCTTCTGCACAGCAAAG Assay 356 (SEQ ID NO: 483) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC DB1 / 151380125.4 126 NTR-016PC / 119601-5016 TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAA GCTTCTGCACAGCAAAG Assay 357 (SEQ ID NO: 484) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACA AGCACAGGCAACCAAAGCAAAAATGGACAAATGGGATCACATCAAGTTAAAAAGCTTCTG CACAGCAAAG Assay 358 (SEQ ID NO: 485) DB1 / 151380125.4 127 NTR-016PC / 119601-5016 TCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACT ATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGAT TTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 359 (SEQ ID NO: 486) ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAA Assay 360 (SEQ ID NO: 487) TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAA Assay 361 (SEQ ID NO: 488) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 362 (SEQ ID NO: 489) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 363 (SEQ ID NO: 490) DB1 / 151380125.4 128 NTR-016PC / 119601-5016 TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGA TTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 364 (SEQ ID NO: 491) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTA ATACCCCACAAGCACAGGCAACCAA Assay 365 (SEQ ID NO: 492) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAA Assay 366 (SEQ ID NO: 493) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG DB1 / 151380125.4 129 NTR-016PC / 119601-5016 ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAA GCACAGGCAACCAA Assay 367 (SEQ ID NO: 494) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAA CCAA Assay 368 (SEQ ID NO: 495) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 369 (SEQ ID NO: 496) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC DB1 / 151380125.4 130 NTR-016PC / 119601-5016 ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGG GCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 370 (SEQ ID NO: 497) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAA GATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 371 (SEQ ID NO: 498) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA DB1 / 151380125.4 131 NTR-016PC / 119601-5016 CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTG AGTAATACCCCACAAGCACAGGCAACCAA Assay 372 (SEQ ID NO: 499) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAA TACCCCACAAGCACAGGCAACCAA Assay 373 (SEQ ID NO: 500) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAA DB1 / 151380125.4 132 NTR-016PC / 119601-5016 Assay 374 (SEQ ID NO: 501) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCAC AAGCACAGGCAACCAA Assay 375 (SEQ ID NO: 502) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG DB1 / 151380125.4 133 NTR-016PC / 119601-5016 AAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGG CAACCAA Assay 376 (SEQ ID NO: 503) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 377 (SEQ ID NO: 504) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA DB1 / 151380125.4 134 NTR-016PC / 119601-5016 CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCT GGGCAAAGATTTCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 378 (SEQ ID NO: 505) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATT TCTTGAGTAATACCCCACAAGCACAGGCAACCAA Assay 379 (SEQ ID NO: 506) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA DB1 / 151380125.4 135 NTR-016PC / 119601-5016 AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATA CCCCACAAGCACAGGCAACCAA Assay 380 (SEQ ID NO: 507) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTGGTCTGGGCAAAGATTTCTTGAGTAATACCCCACA AGCACAGGCAACCAA Assay 381 (SEQ ID NO: 508) DB1 / 151380125.4 136 NTR-016PC / 119601-5016 TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTG Assay 382 (SEQ ID NO: 509) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGA CATTG Assay 383 (SEQ ID NO: 510) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 384 (SEQ ID NO: 511) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAAC TATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 385 (SEQ ID NO: 512) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTAC TACAAGAAAACATTGGGGAAACTCTCCAGGACATTG DB1 / 151380125.4 137 NTR-016PC / 119601-5016 Assay 386 (SEQ ID NO: 513) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 387 (SEQ ID NO: 514) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAAC ATTGGGGAAACTCTCCAGGACATTG Assay 388 (SEQ ID NO: 515) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA TTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAA CTCTCCAGGACATTG Assay 389 (SEQ ID NO: 516) DB1 / 151380125.4 138 NTR-016PC / 119601-5016 AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTG Assay 390 (SEQ ID NO: 517) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 391 (SEQ ID NO: 518) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAA ACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG DB1 / 151380125.4 139 NTR-016PC / 119601-5016 Assay 392 (SEQ ID NO: 519) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAA CTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 393 (SEQ ID NO: 520) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACT ACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 394 (SEQ ID NO: 521) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA DB1 / 151380125.4 140 NTR-016PC / 119601-5016 AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 395 (SEQ ID NO: 522) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAA ACATTGGGGAAACTCTCCAGGACATTG Assay 396 (SEQ ID NO: 523) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC DB1 / 151380125.4 141 NTR-016PC / 119601-5016 CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGG AAACTCTCCAGGACATTG Assay 397 (SEQ ID NO: 524) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCA GGACATTG Assay 398 (SEQ ID NO: 525) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA DB1 / 151380125.4 142 NTR-016PC / 119601-5016 AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCAAACTATGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 399 (SEQ ID NO: 526) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTA TGAAACTACTACAAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 400 (SEQ ID NO: 527) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC DB1 / 151380125.4 143 NTR-016PC / 119601-5016 GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTAC AAGAAAACATTGGGGAAACTCTCCAGGACATTG Assay 401 (SEQ ID NO: 528) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA DB1 / 151380125.4 144 NTR-016PC / 119601-5016 ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCAAACTATGAAACTACTACAAGAAAA CATTGGGGAAACTCTCCAGGACATTG Assay 402 (SEQ ID NO: 529) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTT AAATCTAAGACCTCA Assay 403 (SEQ ID NO: 530) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCA Assay 404 (SEQ ID NO: 531) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 405 (SEQ ID NO: 532) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 406 (SEQ ID NO: 533) DB1 / 151380125.4 145 NTR-016PC / 119601-5016 CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 407 (SEQ ID NO: 534) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAA TCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 408 (SEQ ID NO: 535) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGA Assay 409 (SEQ ID NO: 536) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA DB1 / 151380125.4 146 NTR-016PC / 119601-5016 AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCA Assay 410 (SEQ ID NO: 537) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGAC CTCA Assay 411 (SEQ ID NO: 538) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 412 (SEQ ID NO: 539) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG DB1 / 151380125.4 147 NTR-016PC / 119601-5016 TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 413 (SEQ ID NO: 540) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 414 (SEQ ID NO: 541) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG DB1 / 151380125.4 148 NTR-016PC / 119601-5016 AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 415 (SEQ ID NO: 542) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCA AATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 416 (SEQ ID NO: 543) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAAT GGATTAAAGACTTAAATCTAAGACCTCA DB1 / 151380125.4 149 NTR-016PC / 119601-5016 Assay 417 (SEQ ID NO: 544) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGA CTTAAATCTAAGACCTCA Assay 418 (SEQ ID NO: 545) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA DB1 / 151380125.4 150 NTR-016PC / 119601-5016 CCCCTATCTCTCGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAG ACCTCA Assay 419 (SEQ ID NO: 546) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAAAAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 420 (SEQ ID NO: 547) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT DB1 / 151380125.4 151 NTR-016PC / 119601-5016 ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA AAATCAAATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 421 (SEQ ID NO: 548) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAAAAATCAA ATCAAAATGGATTAAAGACTTAAATCTAAGACCTCA Assay 422 (SEQ ID NO: 549) AAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGG AAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAAT GAAACTAGACCCCTATCTCTCGCCATATACAA Assay 423 (SEQ ID NO: 550) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG DB1 / 151380125.4 152 NTR-016PC / 119601-5016 TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAA Assay 424 (SEQ ID NO: 551) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCT CTCGCCATATACAA Assay 425 (SEQ ID NO: 552) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATA CAA Assay 426 (SEQ ID NO: 553) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 427 (SEQ ID NO: 554) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG ATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA DB1 / 151380125.4 153 NTR-016PC / 119601-5016 Assay 428 (SEQ ID NO: 555) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATAT GCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 429 (SEQ ID NO: 556) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 430 (SEQ ID NO: 557) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACC CCTATCTCTCGCCATATACAA Assay 431 (SEQ ID NO: 558) DB1 / 151380125.4 154 NTR-016PC / 119601-5016 ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTAT CTCTCGCCATATACAA Assay 432 (SEQ ID NO: 559) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCA TATACAA Assay 433 (SEQ ID NO: 560) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG DB1 / 151380125.4 155 NTR-016PC / 119601-5016 GGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATAC AA Assay 434 (SEQ ID NO: 561) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 435 (SEQ ID NO: 562) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 436 (SEQ ID NO: 563) DB1 / 151380125.4 156 NTR-016PC / 119601-5016 TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCA TATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 437 (SEQ ID NO: 564) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAG AATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 438 (SEQ ID NO: 565) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT DB1 / 151380125.4 157 NTR-016PC / 119601-5016 TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGA CCCCTATCTCTCGCCATATACAA Assay 439 (SEQ ID NO: 566) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAA GATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAG TCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAG AAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACT CCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCA ACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCA AAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAA CCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAG AGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTA AAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAA TGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGAC CCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTG ACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACA GACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTG AACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATA AATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCT CGCCATATACAA Assay 440 (SEQ ID NO: 567) CAATTGATGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCA AAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCA DB1 / 151380125.4 158 NTR-016PC / 119601-5016 CAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACAC GACAAGGATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAG CAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTAT CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA Assay 441 (SEQ ID NO: 568) CAATGTGATACATCATATCAACAGAATGAAGGACAAAAACCATATGATCATTTCAATTGA TGCTGAAAAAGCATTTGATAAAATTCAACATCCCTTCATGATAAAAACCCTCAAAAAACT GGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATATACGACAGACCCACAGCTAG TATCATACTGAATGGGGAAAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGG ATGCCCACTTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAG ACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTT TGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGA ACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGC ATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTAC AATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCT CTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAA AGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAA AGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAAT AGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTAT CCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAG AGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAA CAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGG TGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTG GATATCCATATGCAGAAGAATGAAACTAGACCCCTATCTCTCGCCATATACAA DB1 / 151380125.4 159 NTR-016PC / 119601-5016 Assay 442 (SEQ ID NO: 569) GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 443 (SEQ ID NO: 570) TGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAA CAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAG TGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAA TAAATGGTGCTGGGAAAACTGG Assay 444 (SEQ ID NO: 571) CCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAAT TATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAG ACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTT TCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCT GGGAAAACTGG Assay 445 (SEQ ID NO: 572) CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGG Assay 446 (SEQ ID NO: 573) GCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATA GAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATC CTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGA GCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAAC AGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGT GCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG DB1 / 151380125.4 160 NTR-016PC / 119601-5016 Assay 447 (SEQ ID NO: 574) GTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACA GATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAA TCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAA AGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAA CCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGA ACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACA TACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 448 (SEQ ID NO: 575) AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 449 (SEQ ID NO: 576) TTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAG AAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCA ATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCA AAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACC ACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCA CATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGC ATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACA CCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTC TCTTCAATAAATGGTGCTGGGAAAACTGG Assay 450 (SEQ ID NO: 577) ATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAAC TTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATT GAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATT GTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATA CCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAA DB1 / 151380125.4 161 NTR-016PC / 119601-5016 AGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTA CCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAA AACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTAC AGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTC AATAAATGGTGCTGGGAAAACTGG Assay 451 (SEQ ID NO: 578) CAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAA GTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAA GAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGAC ACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATG TCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACA TTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGA ATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTC AAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACAC ATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTC ATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGG TGCTGGGAAAACTGG Assay 452 (SEQ ID NO: 579) ACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAA ATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAAT CCCATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGT GAAAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAA AAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCAT ACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTT CACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGC CAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATT ATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGA CCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTT CGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTG GGAAAACTGG Assay 453 (SEQ ID NO: 580) CCTTGTTTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAAC TATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAAT DB1 / 151380125.4 162 NTR-016PC / 119601-5016 CAGTAGCATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCC CATTTACAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGA AAGATCTCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAA AATGGAAAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATAC TACCCAAAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCA CAGAAATAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCA AAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTAT ACTACAGAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACC AATGGAACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCG ACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGG AAAACTGG Assay 454 (SEQ ID NO: 581) GACAAGAGAAAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGT TTGCAGATGATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAG AACTGATAAACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAG CATTTCTATATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTA CAATAGCCACAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATC TCTACAATGAAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGA AAGATATTCCATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCA AAGCAATCTACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAA TAGAAAAAACAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTA TCCTGAGCAAAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACA GAGCTATAGTAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGA ACAGAATAGAGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAG GTGCCAAGAACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACT GG Assay 455 (SEQ ID NO: 582) TTTCACCACTGTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGA AAGAAATAAAGGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATG ATATGATCTTATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAA ACAAATTCAGTAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTAT ATGCCAACAGTGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCA CAAATAAAATTAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATG AAAACTATAAAACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTC CATGTTCATGGATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCT ACAGATTCAATGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAA DB1 / 151380125.4 163 NTR-016PC / 119601-5016 CAATCCTAAAATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCA AAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAG TAACCAAAACAGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAG AGAACCCAGAAACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGA ACATACACTGGGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 456 (SEQ ID NO: 583) AAAACTGAAAGCCTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACT GTTATTCAACATAGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAA GGGCATCCAAATTGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTT ATATTTGGAAAAACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAG TAAAGTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAG TGAACAATCTGAAAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAAT TAAATACCTAGGAATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAA AACACTGATGAAAGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATG GATTGGAAGAATCAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAA TGCAATCCCTATCAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAA ATTTATATGGAACCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAA AACTGGAGGAATCACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAAC AGCATGGTACTGGCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGA AACAAATCCACACACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTG GGGAAAAGACAGTCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 457 (SEQ ID NO: 584) AAAAGCCATATACGACAGACCCACAGCTAGTATCATACTGAATGGGGAAAAACTGAAAGC CTTTCCTCTAAGATCTGGAACACGACAAGGATGCCCACTTTCACCACTGTTATTCAACAT AGTACTGGAAGTCCTAGCTAGAGCAATCAGACAAGAGAAAGAAATAAAGGGCATCCAAAT TGGAAAGGAAGAAGTCAAATTATCCTTGTTTGCAGATGATATGATCTTATATTTGGAAAA ACCTAAAGACTCCACNAAAAAACTATTAGAACTGATAAACAAATTCAGTAAAGTTGCAGG ATACAAAATCAACATACAAAAATCAGTAGCATTTCTATATGCCAACAGTGAACAATCTGA AAAAGAAATCAAAAAAGTAATCCCATTTACAATAGCCACAAATAAAATTAAATACCTAGG AATTAACTTAACCAAAGAAGTGAAAGATCTCTACAATGAAAACTATAAAACACTGATGAA AGAAATTGAAGAGGACACCAAAAAATGGAAAGATATTCCATGTTCATGGATTGGAAGAAT CAATATTGTTAAAATGTCCATACTACCCAAAGCAATCTACAGATTCAATGCAATCCCTAT CAAAATACCAATGACATTCTTCACAGAAATAGAAAAAACAATCCTAAAATTTATATGGAA CCACAAAAGACCCAGAATAGCCAAAGCTATCCTGAGCAAAAAGAACAAAACTGGAGGAAT CACATTACCTGACTTCAAATTATACTACAGAGCTATAGTAACCAAAACAGCATGGTACTG GCATAAAAACAGACACATAGACCAATGGAACAGAATAGAGAACCCAGAAACAAATCCACA DB1 / 151380125.4 164 NTR-016PC / 119601-5016 CACCTACAGTGAACTCATTTTCGACAAAGGTGCCAAGAACATACACTGGGGAAAAGACAG TCTCTTCAATAAATGGTGCTGGGAAAACTGG Assay 458 (SEQ ID NO: 585) TAAAAACCCTCAAAAAACTGGGTATAGAAGGAACATACCTCAACATAATAAAAGCCATAT ACGACAGACCC...

Claims

NTR-016PC / 119601-5016 CLAIMS:

1. A method for detecting a marker for an inflammatory disease, comprising determining the level of a DNA fragment of a genomic repeat element in a subject sample.

2. The method of claim 1, wherein the DNA fragment is derived from AluYm1.

3. The method of claim 2, wherein the DNA fragment derived from AluYm1 is less than about 300 bp.

4. The method of claim 2 or 3, wherein the DNA fragment derived from AluYm1 is about 200 bp or is less than about 150 bp..

5. The method of any one of claims 2 to 4, wherein the DNA fragment derived from AluYm1 comprises a nucleotide sequence substantially represented by a nucleotide sequence selected from SEQ ID NOs: 128-136, including natural variants thereof.

6. The method of any one of claims 1 to 5, wherein the DNA fragment is amplified from the sample or is detected after direct capture.

7. The method of claim 6, wherein the DNA fragment is amplified by PCR, optionally using forward and reverse primers selected from SEQ ID NOs: 7-127, optionally wherein the forward primer has a nucleotide sequences selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66, and the reverse primers has a nucleotide sequences selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65.

8. The method of claim 7, wherein the DNA fragment is quantified by qPCR, optionally using TAQMAN or similar real time-PCR system.

9. The method of claim 6, wherein the DNA fragment is amplified by isothermal amplification, and optionally wherein the isothermal amplification is Recombinase Polymerase Amplification (RPA), Loop-Mediated Isothermal Amplification (LAMP), or Single Primer Isothermal Amplification (SPIA).

10. The method of claim 9, wherein the isothermal amplification employs a forward primer having a nucleobase sequence selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, DB1 / 151380125.4 233NTR-016PC / 119601-5016 52, 54, 56, 58, 60, 62, 64, and 66, and optionally a reverse primer having a nucleobase sequence selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65.

11. The method of claim 9 or 10, wherein the DNA fragment is detected and / or quantified by a lateral flow test.

12. The method of claim 11, wherein the DNA fragment is amplified with primer(s) conjugated with a detectable label and a capturable moiety.

13. The method of any one of claims 1 to 12, wherein an elevated level of the DNA fragment is indicative of active inflammatory disease in the subject.

14. The method of claim 13, wherein the inflammatory disease is an autoimmune disease.

15. The method of claim 14, wherein the autoimmune disease is systemic lupus erythematosus (SLE), and optionally involves lupus nephritis.

16. The method of claim 14 or 15, wherein the subject has a loss-of-function mutation in one or both dnase1l3 genes.

17. The method of claim 14, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, vasculitis, inflammatory bowel disease, and dermatomyositis.

18. The method of claim 13, wherein the inflammatory disease is gout.

19. The method of any one of claims 1 to 18, wherein the subject suffers from or is at risk of thrombotic vascular disease, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and sepsis.

20. The method of any one of claims 1 to 19, wherein the sample is blood, serum, plasma, or urine.

21. The method of any one of claims 1 to 20, wherein the subject is tested at a frequency of approximately daily to about once per month. DB1 / 151380125.4 234NTR-016PC / 119601-5016 22. A method for treating a subject for an inflammatory disease, comprising: administering a treatment for the inflammatory disease where the subject exhibits an elevated level of a DNA fragment derived from a repetitive DNA element in a biological sample.

23. The method of claim 22, wherein the treatment is DNase treatment.

24. The method of claim 23, wherein the treatment is parenteral DNase treatment.

25. The method of claim 23 or 24, wherein the DNase is DNase1, DNase1-like 1, DNase1-like 2, or DNase1-like 3.

26. The method of claim 25, wherein the DNase is DNase1-like 3 (D1L3), and which is optionally fused to a carrier protein at its N-terminus either directly or indirectly through a linker, and where the carrier protein is optionally albumin.

27. The method of claim 25 or 26, wherein the D1L3 enzyme has a full or partial deletion of the C-terminal basic domain.

28. The method of any one of claims 22 to 27, wherein the treatment comprises administering an immunosuppressive drug.

29. The method of claim 28, wherein the treatment comprises one or more of corticosteroid, azathiopurine, mycophenolate mofetil, cyclophosphamide, voclosporin, belimumab and anifrolumab.

30. The method of any one of claims 22 to 29, wherein the DNA fragment is greater than 150 base pairs (bp).

31. The method of claim 30, wherein the DNA fragment is derived from AluYm1 and is less than about 300 bp.

32. The method of claim 31, wherein the DNA fragment derived from AluYm1 is about 200 bp, or the DNA fragment is less than about 150 bp.

33. The method of any one of claims 30 to 32, wherein the DNA fragment derived from AluYm1 comprises a nucleotide sequence substantially represented by a nucleotide sequence selected from SEQ ID NOs: 128-136, including natural variants thereof. DB1 / 151380125.4 235NTR-016PC / 119601-5016 34. The method of any one of claims 22 to 33, wherein the DNA fragment is amplified from the sample or is detected after direct capture.

35. The method of claim 34, wherein the DNA fragment is amplified by PCR, optionally using forward and reverse primers, optionally wherein the forward primer has a nucleotide sequence selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66, and the reverse primer has a nucleotide sequence selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65.

36. The method of claim 35, wherein the DNA fragment is quantified by qPCR, optionally using TAQMAN or similar real time-PCR system.

37. The method of claim 36, wherein the DNA fragment is amplified by isothermal amplification, and optionally wherein the isothermal amplification is Recombinase Polymerase Amplification (RPA), Loop-Mediated Isothermal Amplification (LAMP), or Single Primer Isothermal Amplification (SPIA).

38. The method of claim 37, wherein the isothermal amplification employs a forward primer having a nucleobase sequence selected from SEQ ID NOs: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66, and optionally a reverse primer having a nucleobase sequence selected from SEQ ID NOs: 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, and 65.

39. The method of claim 37 or 38, wherein the DNA fragment is detected and / or quantified by a lateral flow test.

40. The method of claim 39, wherein the DNA fragment is amplified with primer(s) conjugated with a detectable label and a capturable moiety.

41. The method of any one of claims 22 to 40, wherein an elevated level of the DNA fragment is indicative of active inflammatory disease in the subject.

42. The method of claim 41, wherein the inflammatory disease is an autoimmune disease. DB1 / 151380125.4 236NTR-016PC / 119601-5016 43. The method of claim 42, wherein the autoimmune disease is systemic lupus erythematosus (SLE), which is optionally mild, moderate, or severe SLE, and which optionally involves lupus nephritis.

44. The method of claim 42, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, vasculitis, inflammatory bowel disease, and dermatomyositis.

45. The method of claim 41, wherein the inflammatory disease is gout.

46. The method of any one of claims 22 to 45, wherein the subject suffers from or is at risk of thrombotic vascular disease, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and sepsis.

47. The method of any one of claims 22 to 46, wherein the sample is blood, serum, plasma, or urine.

48. The method of claim 47, wherein the sample is plasma.

49. The method of claim 48, wherein the plasma is EDTA plasma.

50. The method of any one of claims 47 to 49, wherein the elevated level is elevated as compared to a reference value.

51. The method of claim 50, wherein an EDTA plasma sample is obtained from the subject about 5 minutes to 48 hours after administration of a DNase therapy, which is optionally DNase1-like 3 or a variant thereof.

52. The method of claim 51, wherein an EDTA plasma sample is obtained after at least about 15 minutes, or at least about 30 minutes, or at least about 1 hour, or at least about 2 hours, or at least about 3 hours, or at least about 4 hours, or at least about 6 hours, or at least about 8 hours, or at least about 12 hours, or at least about 18 hours, or at least about 24 hours, or at least about 36 hours, or at least about 48 hours, after administration the DNase therapy.

53. The method of claim 51 or claim 52, wherein the method further comprises comparing relative abundance of the DNA fragment in the EDTA plasma with a baseline DB1 / 151380125.4 237NTR-016PC / 119601-5016 EDTA plasma obtained before administration of the DNase therapy to confirm therapeutic activity of the DNase therapy.

54. The method of claim 47, wherein the sample is serum.

55. The method of claim 54, wherein the serum is obtained prior to and / or after the administration of the treatment.

56. The method of claim 55, wherein the treatment comprises a DNase treatment, which is optionally a DNase1-like 3 or a variant thereof.

57. The method of any one of claims 54 to 56, wherein the method further comprises comparing relative abundance of the DNA fragment in the serum with one or more reference values or one or more baseline values.

58. The method of claim 57, wherein the reference values represent a relative abundance of the DNA fragment in serum for a condition selected from: active state of the inflammatory disease and inactive state of the inflammatory disease.

59. The method of any one of claims 22 to 58, wherein the subject is tested at a frequency of approximately daily to about once per month for an elevated level of the DNA fragment. DB1 / 151380125.4 238

Images